Document:

EX-10.23

 Exhibit 10.23 

Certain identified information has been omitted from this exhibit because it is 

not material and of the type that the registrant treats as private or confidential. 

[***] indicates that information has been omitted. 

NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN ACUITAS
THERAPEUTICS, INC. AND GREENLIGHT BIOSCIENCES INC. 

NON-EXCLUSIVE LICENSE AGREEMENT 

by and between 

ACUITAS THERAPEUTICS, INC. 

and 

GREENLIGHT BIOSCIENCES INC. 

dated 

[________________] 
  

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
			
	 ARTICLE 1
	  	Definitions	  	 	1	 
			
	ARTICLE 2	  	License Grants; Technology Transfer	  	 	9	 
		
	 2.1 Licenses by Acuitas
	  	 	9	 
		
	 2.2 Sublicensing Rights
	  	 	9	 
		
	 2.3 Technology Transfer
	  	 	10	 
		
	 2.4 Updates to Appendix 1.40
	  	 	11	 
			
	 ARTICLE 3
	  	License Limitations	  	 	12	 
			
	 ARTICLE 4
	  	Payments and Royalties	  	 	12	 
		
	 4.1 License Maintenance Fees
	  	 	12	 
		
	 4.2 Milestone Payments
	  	 	12	 
		
	 4.3 Royalties
	  	 	15	 
		
	 4.4 Payment Terms
	  	 	15	 
			
	 ARTICLE 5
	  	Ownership and Inventorship of IP	  	 	17	 
			
	 ARTICLE 6
	  	Patent Prosecution and Maintenance	  	 	18	 
		
	 6.1 Generally
	  	 	18	 
		
	 6.2 Election Not to Prosecute or Maintain or Pay Patent Costs
	  	 	18	 
		
	 6.3 Regulatory Exclusivity Periods
	  	 	18	 
		
	 6.4 Patent Listings
	  	 	18	 
		
	 6.5 Cooperation
	  	 	18	 
			
	 ARTICLE 7
	  	Patent Enforcement and Defense	  	 	19	 
		
	 7.1 Notice; General
	  	 	19	 
		
	 7.2 Enforcement and Defense
	  	 	19	 
			
	 ARTICLE 8
	  	Confidentiality	  	 	21	 
		
	 8.1 Confidential Information
	  	 	21	 
		
	 8.2 Restrictions
	  	 	22	 
		
	 8.3 Exceptions
	  	 	22	 
		
	 8.4 Permitted Disclosures
	  	 	22	 
		
	 8.5 Return of Confidential Information
	  	 	23	 
		
	 8.6 Publications
	  	 	23	 

  
 i 

							
	 8.7 Terms of this License Agreement; Publicity
	  	 	23	 
			
	ARTICLE 9	  	Warranties; Limitations of Liability; Indemnification	  	 	24	 
		
	 9.1 Representations and Warranties
	  	 	24	 
		
	 9.2 Additional Representations of Acuitas
	  	 	24	 
		
	 9.3 Disclaimers
	  	 	26	 
		
	 9.4 No Consequential Damages
	  	 	26	 
		
	 9.5 Performance by Others
	  	 	26	 
		
	 9.6 Indemnification
	  	 	26	 
		
	 9.7 Insurance
	  	 	28	 
			
	ARTICLE 10	  	Term and Termination	  	 	29	 
		
	 10.1 Term
	  	 	29	 
		
	 10.2 Termination by Acuitas
	  	 	29	 
		
	 10.3 Termination by GreenLight
	  	 	29	 
		
	 10.4 Termination Upon Bankruptcy
	  	 	30	 
		
	 10.5 Effects of Termination
	  	 	31	 
		
	 10.6 Survival
	  	 	31	 
			
	ARTICLE 11	  	General Provisions	  	 	31	 
		
	 11.1 Dispute Resolution
	  	 	31	 
		
	 11.2 Cumulative Remedies and Irreparable Harm
	  	 	32	 
		
	 11.3 Relationship of Parties
	  	 	33	 
		
	 11.4 Compliance with Law
	  	 	33	 
		
	 11.5 Governing Law
	  	 	33	 
		
	 11.6 Counterparts; Facsimiles
	  	 	33	 
		
	 11.7 Headings
	  	 	33	 
		
	 11.8 Waiver of Rule of Construction
	  	 	33	 
		
	 11.9 Interpretation
	  	 	34	 
		
	 11.10 Binding Effect
	  	 	34	 
		
	 11.11 Assignment
	  	 	34	 
		
	 11.12 Notices
	  	 	34	 
		
	 11.13 Amendment and Waiver
	  	 	35	 
		
	 11.14 Severability
	  	 	35	 
		
	 11.15 Entire Agreement
	  	 	35	 
		
	 11.16 Force Majeure
	  	 	35	 

  
 ii 

 List of Appendices 

 

			
	 Appendix 1.29
	  	Jointly Owned Patents
		
	 Appendix 1.38
	  	Licensed Product including all Targets
		
	 Appendix 1.40
	  	Patents within the Licensed Technology
		
	 Appendix 9.2
	  	Exceptions to Acuitas’ Representations and Warranties in Section 9.2

  
 iii 

 Non-Exclusive License Agreement 

This Non-Exclusive License Agreement (“License Agreement”), dated as of
[                ] (the “License Agreement Effective Date”), is made by and between Acuitas Therapeutics, Inc., a British Columbia corporation
(“Acuitas”), and GreenLight Biosciences Inc., a Delaware corporation (“GreenLight”). Each of Acuitas and GreenLight may be referred to herein as a “Party” or together as the
“Parties.” 
 WHEREAS, Acuitas has proprietary LNP Technology (as defined below); 

WHEREAS, GreenLight has expertise and intellectual property relating to gene editing therapeutics, including mRNA Constructs (as
defined below) and Genome Editing Constructs (as defined below); 
 WHEREAS, Acuitas and GreenLight are parties to that certain
Development and Option Agreement (dated —, 2020) (the “Development and Option Agreement”), pursuant to which GreenLight has options to take licenses under the Licensed Technology (as defined below) with respect to
GreenLight’s Genome Editing Constructs and mRNA Constructs; and 
 WHEREAS, pursuant to the terms of the Development and Option
Agreement, GreenLight has exercised an option with respect to the Licensed Products and the Parties are now entering into a licensing arrangement whereby GreenLight will have a license under the Licensed Technology to develop and commercialize
Licensed Products (as defined below). 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other
good and valuable consideration, the amount and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 

Definitions 
 The following terms
and their correlatives will have the following meanings: 
 1.1 “Acuitas Indemnitees” has the meaning set forth in
Section 9.6(a). 
 1.2 “Acuitas Patents” has the meaning set forth in Section 7.2(a)(i). 

1.3 “Acuitas Background Technology” has the meaning set forth in the Development and Option Agreement. 

1.4 “Acuitas Technology” has the meaning set forth in the Development and Option Agreement. 

1.5 “Acuitas Sole Technology” has the meaning set forth in the Development and Option Agreement. 

  
 1 

 1.6 “Affiliate” of a person or entity means any other person or
entity which (directly or indirectly) is controlled by, controls or is under common control with such person or entity. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms
“controlled by” and “under common control with”) as used with respect to an entity will mean (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast more than fifty percent
(50%) of the votes in the election of directors, or (b) in the case of a non-corporate entity, direct or indirect ownership of more than fifty percent (50%) of the equity interests with the power to
direct the management and policies of such entity, provided that if local Law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local Law, be owned by
foreign interests. 
 1.7 “Calendar Quarter” means the respective periods of three (3) consecutive calendar
months ending on March 31, June 30, September 30 and December 31. 
 1.8 “cGMP” means current Good
Manufacturing Practices as specified in Parts 210 and 211 of Title 21 of the U.S. C.F.R., ICH Guideline Q7A, or equivalent Laws of an applicable Regulatory Authority at the time of manufacture. 

1.9 “CMO” has the meaning set forth in Section 2.3(a). 

1.10 “Combination Product” means a product that includes at least one additional active ingredient other than a
Licensed Product, or includes at least one proprietary drug delivery system or other proprietary device, in each case sold in conjunction with or used in combination with a Licensed Product (whether packaged together or packaged separately but sold
together for a single price). Drug delivery vehicles and excipients shall not be deemed to be “active ingredients,” except in the case where such delivery vehicle or excipient is recognized as an active ingredient in accordance with 21
C.F.R. 210.3(b)(7) or equivalent Laws in other jurisdictions, provided however, should lipid nanoparticles comprised in a Licensed Product be characterized as “active ingredients” at any time during the Term, such lipid nanoparticles will
not be considered an “active ingredient” for the purposes of this definition. 
 1.11 “Confidential
Information” has the meaning set forth in Section 8.1. 
 1.12 “Control” or
“Controlled” means, with respect to a particular Technology, Acuitas owns or has a license to use and practice such Technology and has the right to grant a license or sublicense to such Technology without violating the terms of any
agreement with any Third-Party and without owing any milestone, royalty or other monetary obligations to a Third-Party under the terms of any agreement with such Third-Party. 

1.13 “Covered” and “Covering” means, with reference to a Licensed Product, that without the licenses
granted to GreenLight hereunder, the manufacture, development or commercialization of such Licensed Product would infringe a Valid Claim of an LNP Technology Patent. 

1.14 “Development and Option Agreement” has the meaning set forth in the Preamble. 

1.15 “Diligent Efforts” means, with respect to the efforts to be expended by each Party, active and sustained efforts
to conduct the applicable activity, or to attempt to achieve the applicable requirement or goal, in a prompt and expeditious manner, as is reasonably practicable under the circumstances and the terms of this Agreement. 

  
 2 

 1.16 “Disclosing Party” has the meaning set forth in
Section 8.1. 
 1.17 “Executive Officers” has the meaning set forth in Section 11.1(b). 

1.18 “Field of Use” means all human therapeutic or prophylactic uses of Licensed Products. 

1.19 “First Commercial Sale” means the first sale for use or consumption for which revenue has been recognized of any
Licensed Product in a country after all required Marketing Authorization Approvals for commercial sale of such Licensed Product, and required pricing or reimbursement approvals, have been obtained in such country. 

1.20 “FTE” means the work of a full-time person for one year, or more than one person working the equivalent of a
full-time person for one year, where “full-time” is determined by the standard practices in the biopharmaceutical industry in the geographic area in which such personnel are working, but means 1840 hours per year, in the performance of the
agreed activities for the Technology Transfer, including scientific management oversight as reasonably required. 
 1.21 “FTE
Costs” mean the actual FTEs employed by Acuitas in the conduct of the agreed activities for the Technology Transfer multiplied by an annual rate per FTE equal to [***] (US[***]), which may be prorated on a daily or hourly basis as
necessary. Such FTE Costs represent reimbursement for all costs of FTEs in providing such activities (including salaries and benefits, lab supplies, reagents, equipment and overhead, as well as other G&A costs). 

1.22 “GAAP” means generally accepted accounting principles in the United States. 

1.23 “GMP” means current good manufacture practices as defined under regulations promulgated by the U.S. Food and Drug
Administration. 
 1.24 “GreenLight Indemnitees” has the meaning set forth in Section 9.6(b). 

1.25 “Indemnification Claim Notice” has the meaning set forth in Section 9.6(c). 

1.26 “Indemnified Party” has the meaning set forth in Section 9.6(c). 

1.27 “Indemnifying Party” has the meaning set forth in Section 9.6(c). 

1.28 “Insolvency Legislation” has the meaning set forth in Section 10.4. 

1.29 “Joint IP” means the Joint IP as such term is defined in the Development and Option Agreement. 

1.30 “Jointly Owned Patents” means the Patents listed in Appendix 1.29 hereto, as amended from time to time.

  
 3 

 1.31 “Know-How” means all
Materials and all confidential and proprietary commercial, technical, scientific and other know-how and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions,
skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical,
physical and analytical, preclinical, clinical, safety, manufacturing and quality control data and know-how, including study designs and protocols), in all cases, provided such information is confidential and
proprietary, and regardless of whether patentable, in written, electronic or any other form now known or hereafter developed. 
 1.32
“Know-How Royalties” has the meaning set forth in Section 4.3(a). 

1.33 “Late Stage Development” means, with respect to a product, that first dosing under Phase 2 Studies has been
initiated. 
 1.34 “Law” or “Laws” means all laws, statutes, rules, regulations, orders, judgments
or ordinances having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. 

1.35 “License Agreement” has the meaning set forth in the Preamble. 

1.36 “License Agreement Effective Date” has the meaning set forth in the Preamble. 

1.37 “Licensed Antibody Product” has the meaning set forth in the Development and Option Agreement. 

1.38 “Licensed Genome Editing Product” has the meaning set forth in the Development and Option Agreement. 

1.39 “Licensed Product” means the [***]with respect to which GreenLight has exercised the Option under the Development
and Option Agreement, which consists of the Targets set forth on Appendix 1.38. For the avoidance of doubt, the term Licensed Product in respect of a given Target encompasses all variants of such Target, including the wild types, naturally
occurring variants, engineered variants wherein modifications to the native amino acid sequence have been made (for example, mutated versions, derivatives or fragments) and species homologs and orthologs thereof, provided, however, that any such
naturally occurring variant, engineered variant or species homolog or ortholog possesses substantially similar biological activity to such Target(s) (for example antigenicity in case of antigens). In the case of [***]GreenLight may submit multiple
[***]for [***]in Appendix 1.38. In the event that GreenLight wishes to include [***]after the Effective Date these additional sequences may be submitted to the Escrow Agent for review. If the Escrow Agent determines that these [***]are not
subject to Pre-Existing Restrictions (at the time of review) and are published [***] for known strains or subtypes of [***] then such [***] will be included in Appendix 1.38. 

1.40 “Licensed Product Royalty Term” has the meaning set forth in Section 4.3(d). 

1.41 “Licensed Technology” means all Acuitas Technology as of the License Agreement Effective Date or generated or
obtained during the Term (including the Acuitas Background Technology, Acuitas Sole Technology and Acuitas’ interest in any Joint IP) necessary or useful for the research, development, manufacture, use or sale of a Licensed Product including
without limitation the , patents listed, in Appendix 1.40 attached hereto to be updated from time to time. 

  
 4 

 1.42 “License Maintenance Fees” means the fees set forth in
Section 4.1. 
 1.43 ”Licensed Vaccine Product” has the meaning set forth in the Development and Option
Agreement. 
 1.44 “LNP” means lipid nanoparticles. 

1.45 “LNP Technology” means any Technology that claims, embodies or incorporates delivery systems (and components
thereof) based on or incorporating LNPs. 
 1.46 “LNP Technology Patent(s)” means Patents comprised in the Licensed
Technology, including any future Patent which will become part of the Licensed Technology during the Term and further including Acuitas’ rights in the Jointly Owned Patents, unless otherwise set forth herein. 

1.47 “Losses” has the meaning set forth in Section 9.6(a). 

1.48 “Major Market Country” means each of the United States, the United Kingdom, Germany, France, Italy, Spain and
Japan. 
 1.49 “Marketing Authorization Approval” means, with respect to a country or extra-national territory, any
and all approvals (including a Biologics License Application approved by the FDA), licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or market a product in such country or some
or all of such extra-national territory. 
 1.50 “Materials” has the meaning set forth in the Development and Option
Agreement. 
 1.51 “Milestone Event” has the meaning set forth in Section 4.2. 

1.52 “Milestone Payment” has the meaning set forth in Section 4.2. 

1.53 “Minimum Royalty” has the meaning set forth in Section 4.4(c). 

1.54 “Net Sales” means, with respect to any Licensed Product, the amount received by GreenLight and its Affiliates
and/or Sublicensees for bona fide sales of such Licensed Product to a Third-Party (other than Affiliates and Sublicensees but including distributors for resale), less: 

(a) discounts (including mandated, trade, cash, quantity, prompt pay and patient program discounts), retroactive price reductions,
commissions, charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments, their agencies, pharmacy benefit managers, and purchasers and reimbursers or to trade customers; 

  
 5 

 (b) credits or allowances actually granted upon claims, damaged or defective goods, refunds,
rejections or returns of, and for uncollectable amounts on, such Licensed Product, including such Licensed Product returned in connection with recalls or withdrawals; 

(c) freight, postage, shipping, handling and insurance charges for delivery of such Licensed Product; 

(d) taxes or duties levied on, absorbed or otherwise imposed on the sale of such Licensed Product, including value-added taxes, or other
governmental charges otherwise imposed upon the billed amount, such as the annual fee imposed on pharmaceutical manufacturer by the US government, as adjusted for rebates and refunds; 

(e) any invoiced amounts from a prior period which are not collected and are written off by GreenLight, its Affiliates or its or their
Sublicensees, including bad debts; 
 (f) wholesaler and distributor administration fees and other reasonable fees paid to selling agents,
group purchasing organizations, Third-Party payors, other contractees and managed care entities, in each case with respect to such Licensed Product; and 

(g) other customary deductions taken in the ordinary course of business in accordance with GAAP. 

Net Sales shall not include any payments among GreenLight, its Affiliates and Sublicensees. Net Sales shall be determined in accordance with
GAAP, consistently applied. 
 Net Sales for any Combination Product shall be calculated on a country-by-country basis by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B), where A is the weighted average price paid for the Licensed Product contained in such Combination
Product sold separately in finished form in such country, and B is the weighted average invoice price paid for the other active ingredients (or proprietary drug delivery system or proprietary other device) contained in such Combination Product sold
separately in finished form in such country, if such Licensed Product and such other active ingredients (or proprietary drug delivery system or other proprietary device) are each sold separately in such country. 

Net Sales of the Licensed Product for any Combination Product if the Licensed Product or other active ingredients (or proprietary drug
delivery system or other proprietary device) in such Combination Product are not sold separately in such country, shall be calculated by multiplying the Net Sales of the Combination Product by a fraction, the numerator of which shall be the fair
market value of the Licensed Product as if sold separately (in accordance with GAAP), and the denominator of which shall be the aggregate fair market value of all the other active ingredients of such Combination Product, including the Licensed
Product, as if sold separately. The fair market value of each component of a Combination Product will be a determined by a Third-Party expert selected by GreenLight and reasonably acceptable to Acuitas. 

1.55 “Option Exercise Fee” has the meaning set forth in the Development and Option Agreement. 

1.56 “Party” and “Parties” has the meaning set forth in the Preamble. 

  
 6 

 1.57 “Patent(s)” means an (a) issued patent, a patent
application, and a future patent issued from any such patent application, (b) a future patent issued from a patent application filed in any country worldwide which claims priority from a patent or patent application included in (a), (c) any
additions, divisions, continuations, continuations-in-part, invention certificates, substitutions, reissues, reexaminations, extensions, registrations, utility models,
supplementary protection certificates and renewals based on any patent or patent application under (a) or (b), but not including any rights that give rise to regulatory exclusivity periods (other than supplementary protection certificates,
which will be treated as “Patents” hereunder), and (d) any counterpart of any patent or patent application under (a), (b) or (c) filed in any country worldwide. 

1.58 “Patent Costs” means the reasonable, documented,
out-of-pocket costs and expenses paid to outside legal counsel, and filing and maintenance expenses, actually and reasonably incurred by a Party in prosecuting and
maintaining Patents. 
 1.59 “Patent Royalties” has the meaning set forth in Section 4.3(a). 

1.60 “Permitted Subcontractor” has the meaning set forth in Section 2.2(c). 

1.61 “Phase 1 Study” means a human clinical trial of a Licensed Product in any country, the primary purpose of which
is the determination of safety and which may include the determination of metabolism and pharmacologic actions of the Licensed Product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on
effectiveness, as more fully defined in 21 C.F.R. §312.21(a) or its successor regulation, or the equivalent in any foreign country. 

1.62 “Phase 2 Study” means a human clinical trial of a Licensed Product in any country, the primary purpose of which
is to evaluate the effectiveness of the Licensed Product for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the Licensed
Product, as more fully defined in 21 C.F.R. §312.21(b) or its successor regulation, or the equivalent in any foreign country. 

1.63 “Phase 3 Study” means a human clinical trial of a Licensed Product in any country, the primary purpose of which
is to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the Licensed Product and to provide an adequate basis for physician labeling, as more fully defined in 21
C.F.R. §312.21(c) or its successor regulation, or the equivalent in any foreign country. 
 1.64 “Receiving
Party” has the meaning set forth in Section 8.1. 
 1.65 “Regulatory Authority” means any national
(e.g., the United States Food and Drug Administration (“FDA”)), supra-national (e.g., the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental authority, in
any jurisdiction in the world, involved in the granting of Marketing Authorization Approval. 

  
 7 

 1.66 “Regulatory Exclusivity” means with respect to any country or
other jurisdiction in the Territory, an additional market protection, other than Patent protection, granted by a Regulatory Authority in such country or other jurisdiction which confers an exclusive commercialization period during which GreenLight
or its Affiliates or Sublicensees have the exclusive right to market and sell a Licensed Product in such country or other jurisdiction through a regulatory exclusivity right (e.g., new chemical entity exclusivity, new use or indication exclusivity,
new formulation exclusivity, orphan drug exclusivity, pediatric exclusivity, or any applicable data exclusivity). 
 1.67
“Royalties” has the meaning set forth in Section 4.3(a). 
 1.68 “Royalty Term” has the
meaning set forth in Section 4.3(d). 
 1.69 “Solely Owned Technology” has the meaning set forth in Article 5.

 1.70 “Sublicensee” means any Third-Party that is granted a sublicense as permitted by Section 2.2, either
directly by GreenLight or its Affiliates or indirectly by any other Sublicensee hereunder. 
 1.71 “Targets” has the
meaning set forth in the Development and Option Agreement. 
 1.72 “Technology” means collectively Patents and Know-How. 
 1.73 “Technology Evaluation Agreement” has the meaning set forth in
the Development and Option Agreement. 
 1.74 “Technology Transfer” has the meaning set forth in
Section 2.3(a). 1.75. “Technology Transfer Plan” has the meaning set forth in Section 2.3(a). 1.76. “Term” has the meaning set forth in Section 10.1. 

1.75 “Territory” means worldwide. 

1.76 “Third-Party” means any person or entity other than GreenLight, Acuitas and their respective Affiliates. 

1.77 “Third-Party Claims” has the meaning set forth in Section 9.6(a). 

1.78 “Third-Party Royalty Payments” has the meaning set forth in Section 4.3(b). 

1.79 1.81. “Transferred Technology” has the meaning set forth in Section 2.3(a). 

1.80 1.82. “Valid Claim” means a claim of (a) an issued patent included in the Licensed Technology (other
than the Jointly Owned Patents) which has not expired or been abandoned and which has not been disclaimed, canceled, revoked or held invalid or unenforceable by a court or administrative agency of competent jurisdiction from which no further appeal
is possible and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a pending patent application included in the Licensed Technology (other than the Jointly Owned Patents) which claim is being
actively prosecuted and which has not been (i) canceled, (ii) withdrawn from consideration, (iii) finally determined to be unallowable by the applicable governmental authority (and from which no appeal is or can be taken), (iv) abandoned,
or (v) pending for more than five (5) years from the date of priority of such patent application. 

  
 8 

 1.81 “Workplan Data” has the meaning set forth in the Development and
Option Agreement. 
 1.82 “Workplan Leaders” has the meaning set forth in the Development and Option Agreement. 

ARTICLE 2 
 License
Grants; Technology Transfer 
 2.1 Licenses by Acuitas. 

(a) Subject to the terms and conditions of this License Agreement, Acuitas hereby grants to GreenLight : a non-exclusive (except as set forth in subparts (ii) and (iii)) license, with the right to sublicense only as permitted by Section 2.2(b), under the Licensed Technology, to research, develop, have
developed, make, have made, keep, use and have used, sell, offer for sale, have sold, import and have imported, export and have exported and otherwise commercialize and exploit Licensed Products in the Field of Use in the Territory 

(b) Workplan Data. GreenLight may use Workplan Data generated on the Licensed Product to research, develop, have
developed, make, have made, keep, use and have used, sell, offer for sale, have sold, import and have imported, export and have exported and otherwise commercialize and exploit Licensed Products in the Field of Use in the Territory. 

2.2 Sublicensing Rights. 

(a) Transfer. The licenses granted in Section 2.1 are transferable only upon a permitted assignment of
this License Agreement in accordance with Section 11.11. 
 (b) GreenLight Sublicenses. The licenses
granted in Section 2.1 may be sublicensed (with the right to sublicense through multiple tiers), in full or in part, by GreenLight, its Affiliates or Sublicensees to GreenLight’s Affiliates and Third Parties, provided, that for any
sublicense to Third Parties: 
 (i) Each sublicense will be in writing and on terms consistent with and subject to the terms of this
License Agreement; 
 (ii) GreenLight will provide Acuitas with a copy of any sublicense agreement with a Sublicensee within thirty
(30) days of execution thereof, which sublicense agreement may be redacted as necessary to protect commercially sensitive information and shall be treated as GreenLight Confidential Information hereunder; 

(iii) GreenLight will be responsible for any and all obligations of such Sublicensee as if such Sublicensee were GreenLight hereunder;
and (iv) Any sublicense granted by GreenLight to any rights licensed to it hereunder shall terminate immediately upon the termination of the license from Acuitas to GreenLight and its Affiliates with respect to such rights,

  
 9 

 
provided that such sublicensed rights shall not terminate if, as of the effective date of such termination pursuant to Sections 10.2, 10.3(a) or 10.4, a Sublicensee is not in material default of
its obligations under its sublicense agreement, and within thirty (30) days of such termination, the Sublicensee agrees in writing to be bound directly to Acuitas under a license agreement substantially similar to this License Agreement with
respect to the rights sublicensed hereunder, substituting such Sublicensee for GreenLight. 
 (c)
Subcontractors. For clarity purposes, GreenLight is entitled to engage contract research organizations, contract manufacturing organizations and other service providers, as well as academic or
non-profit institutions (each a “Permitted Subcontractor”) for the development and manufacture of Licensed Products on behalf of GreenLight. To the extent such Permitted Subcontractors require a
license to perform such subcontracted activities under applicable Laws, GreenLight is entitled to grant a limited research and/or manufacturing sublicense (as applicable) without an obligation to meet the conditions of Section 2.3(b)(ii) and
(iv). 
 2.3 Technology Transfer. 

(a) Technology Transfer. After the License Agreement Effective Date and promptly upon written request by
GreenLight (and in any event within ninety (90) days following designation of the applicable CMO (as defined below), provided such CMO is able to support this timeline), Acuitas will initiate the conduct of a single technology transfer of Know-How relating to the then-current formulation process, raw materials supply and analytical characterization sufficient for the manufacture of Licensed Product (the “Transferred Technology”), to
GMP contract manufacturing organization (together with GreenLight as a manufacturer, for purposes of this Section 2.3(a), “CMOs”)) designated by GreenLight subject to Acuitas’ prior written consent, which will not be
unreasonably withheld, conditioned or delayed and in accordance with the Development and Option Agreement (the “Technology Transfer”) pursuant to a mutually agreed plan (the “Technology Transfer Plan”). In addition,
Acuitas will provide to GreenLight such other Confidential Information and Know-How relating to the then-current formulation of Licensed Product as reasonably necessary to manufacture Licensed Product, and
GreenLight shall be entitled to use and disclose such Confidential Information and Know-How for such purposes. Acuitas will exercise Diligent Efforts to enable such CMOs to manufacture such Licensed Product.
Initiation of such technology transfer will be determined by GreenLight and will be for the then current formulation of the Licensed Product. Acuitas will be reimbursed for such activities by GreenLight on an FTE basis and GreenLight will also be
responsible for all external costs incurred by Acuitas relating to transfer of the Licensed Product formulation to such CMO provided such costs have been approved by GreenLight in advance. For clarity, the then-current formulation of the Licensed
Product shall mean a single LNP formulation previously tested by GreenLight in accordance with the Workplan and as determined by the GreenLight (as defined in the Development and Option Agreement). Once the Licensed Product formulation is
transferred to such CMO, GreenLight will assume responsibilities for future manufacturing of Licensed Product. Acuitas will provide reasonably requested ongoing technical support including assistance with any INDs if requested by GreenLight with
such support reimbursed on a time, materials and FTE basis. 

  
 10 

 (b) Activities. Acuitas shall in particular: 

(i) transfer to the CMO all documents relating to Licensed Technology necessary or useful for the manufacture of Licensed Products,
including documents relating to the Transferred Technology, and which are owned by Acuitas; 
 (ii) allow GreenLight to monitor the
progress of the transfer and to confirm whether the transfer has been successfully completed; 
 (iii) provide training to the CMO
by fully qualified and experienced employees or contractors of Acuitas in respect of the manufacture of Licensed Products. Unless otherwise agreed, the training will be provided at the CMO’s site. For purposes of the training, Acuitas shall
make available at least two (2) experienced and competent Acuitas FTEs, the specific qualification of the Acuitas FTEs and the details of the training to be further described in the Technology Transfer Plan; and 

(iv) provide ongoing technical support in relation to the Transferred Technology to the CMO, as reasonably requested by GreenLight
from time to time. 
 (c) Diligence. Acuitas shall perform the Technology Transfer in a professional manner and
in accordance with the Technology Transfer Plan and use Diligent Efforts to meet the objectives and timelines set forth therein. Acuitas shall ensure that the CMO is trained and empowered to perform the manufacturing. It is understood that
successful Technology Transfer cannot be guaranteed and Acuitas will not be found not to have used Diligent Efforts based on the failure by the CMO to achieve any particular result, unless Acuitas contributed to or caused such failure. 

(d) Intellectual Property. Any intellectual property generated during the Technology Transfer shall be governed by
the intellectual property provisions of the Development and Option Agreement applicable to inventions arising out of the Program (as defined therein). 

(e) Payment. GreenLight will reimburse Acuitas on a Calendar Quarter-by-Calendar Quarter basis for (i) FTE Costs based on the number of hours worked by Acuitas’ FTEs, and (ii) any reasonable external costs approved by GreenLight in advance that are
incurred by Acuitas, in each case in the performance of the agreed technology transfer activities for the Technology Transfer. Acuitas will send a reasonably detailed invoice to GreenLight no later than fifteen (15) days after the end of each
Calendar Quarter, which invoice shall include a summary of all activities by the name of each individual, number of hours devoted by each such individual, and the type/activity performed by each such individual during such Calendar Quarter, and all
external costs incurred by Acuitas during such Calendar Quarter. GreenLight agrees to pay undisputed amounts in each such invoice within forty-five (45) days of GreenLight’s receipt thereof. 

2.4 Updates to Appendix 1.40. Upon GreenLight’s written request no more frequently than once every twelve
(12) months Acuitas shall notify GreenLight of Patents that are added to the Licensed Technology following the License Agreement Effective Date, and anyPatents that are no longer Licensed Technology because they have been abandoned or
discontinued in accordance with the terms of Section 6.2. Appendix 1.40 shall be automatically updated to include any such added or deleted Patents. 

  
 11 

 ARTICLE 3 

License Limitations 

No licenses or other rights are granted by Acuitas hereunder to use any trademark, trade name, trade dress or service mark owned or otherwise
Controlled by Acuitas or any of its Affiliates. All licenses and other rights are or shall be granted only as expressly provided in this License Agreement, and no other licenses or other rights are or shall be created or granted by either Party
hereunder by implication, estoppel or otherwise. 
 ARTICLE 4 

Payments and Royalties 

4.1 License Maintenance Fees. A license maintenance fee of, for the first and second Options under the Development
and Option Agreement, [***], and for the third Option[***], which in each case will be payable on the first and each subsequent anniversary of the License Agreement Effective Date until such time as the first dosing of the first patient in the first
Phase 1 Study for the Licensed Product anywhere in the Territory is initiated. For each Licensed Product, in the year in which the Milestone Payment for first dosing of the first patient in the first Phase 1 Study for a Licensed Product anywhere in
the Territory is achieved, Acuitas will credit the License Maintenance Fee for that year on a pro rata basis against the Milestone Payment for such Milestone Event. For clarity, this pro rata credit will be up to the maximum amount owing on the
milestone payable on initiation of the first Phase 1 for the remaining months in the year to which the License Maintenance Fee applies. 

4.2 Milestone Payments. GreenLight will make milestone payments (each, a “Milestone Payment”) to Acuitas
upon the first occurrence of each of the milestone events (each, a “Milestone Event”) by GreenLight or its Affiliates with respect to the Licensed Product as set forth below in TABLE 4.2. GreenLight will notify Acuitas of the
achievement of each Milestone Event within ten (10) business days of such achievement. Each Milestone Payment will be payable to Acuitas by GreenLight within forty-five (45) days of the achievement of the specified Milestone Event and such
payments when owed or paid will be non-refundable and non-creditable. If one or more of the Milestone Events set forth below are not achieved with respect to the
Licensed Product for any reason, the payment for such skipped Milestone Event will be due at the same time as the payment for the next achieved Milestone Event for the Licensed Product. For clarity, each Milestone Payment is payable a maximum of one
(1) time only. 
 TABLE 4.2– Milestone Events 

First License to be taken under the Development and Option Agreement 
  

			
	 Milestone Event
	  	 Milestone Payment

	[***]	  	[***]

  
 12 

			
	 Milestone Event
	  	 Milestone Payment

	Phase 1 Study for a Licensed Product anywhere in the Territory	  	 [***]

	[***]Phase 2 Study for a Licensed Product anywhere in the Territory	  	[***]
		
	[***]Phase 3 Study for a Licensed Product anywhere in the Territory	  	[***]
		
	First Marketing Authorization Approval by a Regulatory Authority for a Licensed Product in a Major Market Country	  	[***]
		
	First Commercial Sale of a Licensed Product in a Major Market Country	  	 [***]

		
	First achievement of aggregate Net Sales of Licensed Products in a calendar year in the Territory equal to or greater than [***]	  	 [***]

 Second License to be taken under the Development and License Agreement 

 

			
	 Milestone Event
	  	 Milestone Payment

	[***]Phase 1 Study for a Licensed Product anywhere in the Territory	  	 [***]

		
	[***]Phase 2 Study for a Licensed Product anywhere in the Territory	  	[***]
		
	[***]Phase 3 Study for a Licensed Product anywhere in the Territory	  	 [***]

		
	First Marketing Authorization Approval by a Regulatory Authority for a Licensed Product in a Major Market Country	  	[***]

  
 13 

			
	 Milestone Event
	  	 Milestone Payment

	First Commercial Sale of a Licensed Product in a Major Market Country	  	[***]
		
	First achievement of aggregate Net Sales of Licensed Products in a calendar year in the Territory equal to or greater than [***]	  	 [***]

 Third License to be taken under the Development and License Agreement 

 

			
	 Milestone Event
	  	 Milestone Payment

	[***]Phase 1 Study for a Licensed Product anywhere in the Territory	  	[***]
		
	[***]Phase 2 Study for a Licensed Product anywhere in the Territory	  	 [***]

		
	[***]Phase 3 Study for a Licensed Product anywhere in the Territory	  	[***]
		
	First Marketing Authorization Approval by a Regulatory Authority for a Licensed Product in a Major Market Country	  	 [***]

		
	First Commercial Sale of a Licensed Product in a Major Market Country	  	 [***]

		
	First achievement of aggregate Net Sales of Licensed Products in a calendar year in the Territory equal to or greater than [***]	  	 [***]

  
 14 

 4.3 Royalties. 

(a) Royalties. Subject to the Royalty Term, GreenLight will pay to Acuitas a royalty equal to [***] on Net Sales
of all Licensed Products sold by GreenLight, its Affiliates, or Sublicensees in the Territory for which, but for the license granted to GreenLight hereunder, the manufacture or sale of such Licensed Product would infringe a Valid Claim of an LNP
Technology Patent in such country (“Patent Royalties”). If, at any time during the Royalty Term, the manufacture or sale of a Licensed Product in a particular country would not infringe a Valid Claim of an LNP Technology Patent,
then the Royalty rate used to calculate royalty payments on Net Sales of such Licensed Product in such country shall be the Minimum Royalty (“Know-How Royalties,” and together with the Patent
Royalties, the “Royalties”). 
 (b) Third-Party Royalty Payments. If GreenLight or its
Affiliate or Sublicensee considers it necessary or useful to obtain a license from any Third-Party under Technology relating to LNP Technology in order to develop, manufacture or commercialize a Licensed Product, the amount of GreenLight’s
Royalty obligations under Section 4.3(a) will be reduced by [***] of the amount of the royalty payments made to such Third-Party (“Third-Party Royalty Payments”), provided, however, that such reduction shall not result in less
than the Minimum Royalty. 
 (c) Minimum Royalty. In no event will the Royalty payable by GreenLight to
Acuitas for any Licensed Product and without regard to any Royalty reductions under subparagraph (a) and/or (b) above, be less than the Royalty payable using a royalty rate of [***] (the “Minimum Royalty”). 

(d) Royalty Term. The Royalty term (“Royalty Term”) shall be determined on a country-by-country and Licensed Product-by-Licensed Product basis and shall commence on the
First Commercial Sale of a Licensed Product in such country and shall expire on the last to occur of (i) the expiration of the last to expire Valid Claim in the Licensed Technology that Covers the Licensed Product in such country, (ii) the
expiration of any period of Regulatory Exclusivity, if any, for the Licensed Product in such country, and (iii) ten (10) years from the First Commercial Sale of Licensed Product in such country (the “Licensed Product Royalty
Term”). Thereafter, GreenLight’s licenses under Section 2.1 will become irrevocable, fully paid-up and royalty-free on a
country-by-country and Licensed Product-by-Licensed Product basis. 

(e) For the avoidance of doubt, GreenLight’s obligation to pay Royalties under this Section 4.3 is imposed only once
at the applicable Royalty rate set forth in this Section 4.3 with respect to the same unit of Licensed Product, notwithstanding that such Licensed Product may be Covered by more than one Valid Claim of an LNP Technology Patent. 

4.4 Payment Terms. 

(a) Manner of Payment; Invoices. All amounts specified in this License Agreement are in U.S. dollars and all
payments to be made by GreenLight hereunder will be made in U.S. dollars by wire transfer to such bank account as Acuitas may designate. All invoices to be delivered to GreenLight hereunder shall be delivered in accordance with Section 11.12 or
in such other manner specified by GreenLight from time to time. 

  
 15 

 (b) Records and Audits. GreenLight shall keep, and shall cause
each of its Affiliates and Sublicensees, as applicable, to keep adequate books and records of accounting for the purpose of calculating all Royalties payable to Acuitas hereunder. For the three (3) years next following the end of the calendar
year to which each shall pertain, such books and records of accounting of GreenLight (including those of GreenLight’s Affiliates) shall be kept at each of their principal places of business and shall be open for inspection at reasonable times
and upon reasonable notice by an independent certified accountant selected by Acuitas, and which is reasonably acceptable to GreenLight, for the sole purpose of inspecting the Royalties due to Acuitas under this License Agreement. In no event shall
such inspections be conducted hereunder more frequently than once every twelve (12) months or more than once for the same time period. Such accountant must have executed and delivered to GreenLight and its Affiliates a confidentiality agreement
as reasonably requested by GreenLight, which shall include provisions limiting such accountant’s disclosure to Acuitas to only the results and basis for such results of such inspection. The results of such inspection, if any, shall be binding
on both Parties absent manifest error. Any underpayments shall be paid by GreenLight within thirty (30) days of notification of the results of such inspection. Any overpayments shall be fully creditable against amounts payable in subsequent
payment periods, or, upon the request of GreenLight, paid by Acuitas to GreenLight within thirty (30) days of notification of the results of such inspection. Acuitas shall pay for such inspections, except that in the event there is any upward
adjustment in aggregate Royalties payable for any calendar year shown by such inspection of more than [***] of the amount paid, GreenLight shall reimburse Acuitas for any reasonable
out-of-pocket costs of such accountant. 
 (c)
Reports and Royalty Payments. For as long as Royalties are due under Section 4.4, GreenLight shall furnish to Acuitas a written report for each Calendar Quarter, showing the amount of Net Sales of Licensed Products and Royalties
due for such Calendar Quarter. Reports shall be provided within forty-five (45) days of the end of the Calendar Quarter for Net Sales generated by GreenLight and its Affiliates, and within sixty (60) days of the end of the Calendar Quarter
for Net Sales generated by Sublicensees. Royalty payments for each Calendar Quarter shall be due at the same time as the last such written report for the Calendar Quarter. The report shall include, at a minimum, the following information for the
applicable Calendar Quarter, each listed by Licensed Product and by country of sale: (i) the number of units of Licensed Products sold by GreenLight and its Affiliates and Sublicensees on which Royalties are owed to Acuitas hereunder;
(ii) the gross amount received for such sales; (iii) Net Sales; (iv) the amounts of any credits or reductions permitted by Section 4.3; and (v) the computations for any Acuitas currency conversions pursuant to subsection
(d) below. GreenLight will require each Sublicensee to share with GreenLight the information listed in the foregoing clauses as it relates to Net Sales made by such Sublicensee, and to the extent practicable, will include such Sublicensee
information in such report. All such reports shall be treated as Confidential Information of GreenLight. 
 (d) Currency
Exchange. With respect to Net Sales invoiced in U.S. dollars, the Net Sales and the amounts due to Acuitas hereunder will be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency other than U.S. dollars, payments will
be calculated based on standard methodologies employed by GreenLight or its Affiliates or Sublicensees for consolidation purposes for the Calendar Quarter for which remittance is made for Royalties. 

  
 16 

 (e) Taxes. GreenLight may withhold from payments due to Acuitas
amounts for payment of any withholding tax that is required by Law to be paid to any taxing authority with respect to such payments. GreenLight will provide Acuitas all relevant documents and correspondence and will also provide to Acuitas any other
cooperation or assistance on a reasonable basis as may be necessary to enable Acuitas to claim exemption from such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. GreenLight will give proper evidence
from time to time as to the payment of any such tax. The Parties will cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include GreenLight
making payments from a single source in the U.S., where possible. Apart from any such permitted withholding and those deductions expressly included in the definition of Net Sales, the amounts payable by GreenLight to Acuitas hereunder will not be
reduced on account of any taxes, charges, duties or other levies. 
 (f) Blocked Payments. In the event that, by
reason of applicable Law in any country, it becomes impossible or illegal for GreenLight or its Affiliates or Sublicensees to transfer, or have transferred on its behalf, payments owed to Acuitas hereunder, GreenLight will promptly notify Acuitas of
the conditions preventing such transfer and such payments will be deposited in local currency in the relevant country to the credit of Acuitas in a recognized banking institution designated by Acuitas or, if none is designated by Acuitas within a
period of thirty (30) days, in a recognized banking institution selected by GreenLight or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to Acuitas. 

(g) Interest Due. If any payment due to Acuitas under this License Agreement is overdue (and is not subject to a
good faith dispute), then GreenLight will pay interest thereon (before and after any judgment) at an annual rate of the lesser of two percent (2%) above the prime rate as reported in The Wall Street Journal, Eastern Edition, and the maximum rate
permitted by applicable Law, such interest to run from the date upon which payment of such sum became due until payment thereof in full together with such interest. 

(h) Mutual Convenience of the Parties. The Royalty and other payment obligations set forth hereunder have been
agreed to by the Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying Royalties and other amounts to Acuitas. 

ARTICLE 5 
 Ownership
and Inventorship of IP 
 As between the Parties, and except as set forth in Section 2.3(d) or in the Development and Option
Agreement, each Party will own and retain all right, title and interest in and to any and all Know-How, and Patents arising therefrom, that are discovered, created, conceived, developed or reduced to practice
solely by or on behalf of such Party under or in connection with activities under this License Agreement (“Solely Owned Technology”). Subject to the licenses hereunder and the other terms and conditions of this License Agreement or
any other agreement between the Parties, each Party will be solely responsible for the prosecution and maintenance, and the enforcement and defense, of any Patents within its Solely Owned Technology. 

  
 17 

 ARTICLE 6 

Patent Prosecution and Maintenance 

6.1 Generally. As between the Parties and subject to Section 6.2 below, Acuitas will have the sole right, at its
sole cost, to prosecute and maintain LNP Technology Patents. Notwithstanding the foregoing, prosecution and maintenance with respect to the Jointly Owned Patents shall be handled as provided in the Development and Option Agreement provisions for
Joint IP. 
 6.2 Election Not to Prosecute or Maintain or Pay Patent Costs. If Acuitas elects not (i) to file,
prosecute or maintain any LNP Technology Patents for which it is responsible under Section 6.1 in any particular country before the applicable filing deadline or continue such activities once filed in a particular country, or (ii) to pay
the Patent Costs associated with prosecution or maintenance of any such LNP Technology Patents, then in each such case Acuitas will so notify GreenLight, promptly in writing and in sufficient time to enable Acuitas to meet any deadlines by which an
action must be taken to preserve such LNP Technology Patent in such country, if GreenLight so requests. Upon receipt of each such notice by Acuitas, GreenLight will have the right, but not the obligation, to notify Acuitas in writing on a timely
basis that Acuitas should continue the prosecution and/or maintenance of such LNP Technology Patent in the respective country, and thereafter, (a) Acuitas would prosecute and maintain such LNP Technology Patent in such country at the direction
and expense of GreenLight and any other Acuitas Third-Party licensee of such LNP Technology Patent so electing (on a pro rata basis), (b) Acuitas would make available to GreenLight all documentation and correspondence with respect to such LNP
Technology Patent, and (c) GreenLight’s licenses to such LNP Technology Patent under Section 2.1 will automatically become irrevocable, perpetual, fully paid-up and royalty free but such LNP
Technology Patent will thereafter no longer be part of the Licensed Technology in such country for all other purposes of this License Agreement (e.g., such LNP Technology Patent will not be considered for purposes of determining whether a Valid
Claim exists in a particular country). GreenLight is entitled to discontinue the payment of Patent Costs for any LNP Technology Patents at any time, provided that it will so notify Acuitas in writing in time for such discontinuance. 

6.3 Regulatory Exclusivity Periods. With respect to any Patent term extension, supplemental protection certificate or any
other Patent listing or extension with respect to any LNP Technology Patent Covering a Licensed Product, the Parties will discuss and seek to reach mutual agreement, subject to applicable Law, on which LNP Technology Patents will be subject to such
action, and once such agreement is reached, Acuitas will cooperate with such action. Except where required under applicable Law, without the written consent of GreenLight, Acuitas will not apply for, and is not authorized under this License
Agreement to apply for, any Patent term extension, supplemental protection certificate or any other Patent listing or extension required for any regulatory exclusivity periods for any Licensed Product. For the avoidance of doubt, Acuitas is not
restricted from applying for any Patent term extension, supplemental protection certificate or any other Patent listing or extension required for any regulatory exclusivity periods for any product but the Licensed Products. 

6.4 Patent Listings. GreenLight shall have the sole right, in its sole discretion, to make all filings with Regulatory
Authorities in the Territory for the Licensed Products in the FDA’s Orange Book or Purple Book or in response to a biosimilar application under Section 351(k) of the Public Health Service Act, and under any similar or equivalent Laws in other
countries or jurisdictions. For avoidance of doubt, GreenLight shall have the right to include in such filings patents Controlled by Acuitas, as applicable. 

6.5 Cooperation. Each Party will reasonably cooperate with the other Party in those activities involving the LNP
Technology Patents set forth in Sections 6.1 to 6.4. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees and consultants and agents of GreenLight and Acuitas and their respective Affiliates
and Sublicensees to execute all documents, as reasonable and appropriate so as to enable such activities in respect of any such LNP Technology Patents in any country. 

  
 18 

 ARTICLE 7 

Patent Enforcement and Defense 

7.1 Notice; General. To the extent not in breach of an obligation of confidentiality, each Party will promptly notify, in
writing, the other Party upon learning of any actual or suspected infringement of any LNP Technology Patents by a Third-Party, or of any claim of invalidity, unenforceability, or non-infringement of any LNP
Technology Patents, and will, along with such notice, supply the other Party with any evidence in its possession pertaining thereto. Enforcement and defense of Jointly Owned Patents shall be handled pursuant to the Development and Option Agreement
provisions for Joint IP. 
 7.2 Enforcement and Defense. 

(a) Enforcement. 

(i) As between the Parties, Acuitas will have the first right, but not the obligation, at its sole cost to seek to abate any
infringement of the LNP Technology Patents other than the Jointly Owned Patents (the “Acuitas Patents”) by a Third-Party, or to file suit against any such Third-Party for such infringement. If Acuitas elects not to exercise its
first right to take action or to bring suit to prosecute such infringement or to continue such action or suit, it shall notify GreenLight in writing of such election within thirty (30) days after becoming aware of or receipt of the notice of
the infringement or within fifteen (15) days after the election to stop any such action or suit, as applicable. If after the expiration of the thirty (30) day period (or, if earlier, the date upon which Acuitas provides written notice that
it does not plan to bring such action), Acuitas has neither obtained a discontinuance of infringement nor filed suit against any such Third-Party infringer of such Patent, or in the case of an election by Acuitas not to continue to prosecute an
infringement of an Acuitas Patent, GreenLight shall have the right, but not the obligation, to take action or bring suit against such Third-Party infringer of Acuitas Patents to the extent the Acuitas Patents are necessary or useful for the
research, development, manufacturing and commercialization of the Licensed Product but not necessary or useful for the research, development, manufacturing or commercialization of any other LNP comprising product covered by such Acuitas Patent that
is licensed or optioned by Acuitas to a Third-Party or is under Late Stage Development by Acuitas, and Acuitas shall join such suit as plaintiff to the extent required by applicable law, provided that GreenLight shall bear all of the expense of such
abatement action or suit. 
 (ii) Enforcement and defense of the Jointly Owned Patents will be as set forth in the Development and
Option Agreement for Joint IP. 
 (iii) For clarity, GreenLight shall have the sole right to enforce any Patents owned or controlled
by GreenLight, other than (for avoidance of doubt) the LNP Technology Patents. 
 (b) Defense. 

(i) As between the Parties, Acuitas will have the first right, but not the obligation, at its sole cost, to defend against a
declaratory judgment action or other action to the extent challenging the validity or enforceability of any Acuitas Patent. GreenLight will have the right but not the obligation, at its sole cost, to defend against any other declaratory judgment
action or other action challenging any Acuitas Patent that, on the date of first notice of such action, are not necessary or useful for the research, development, manufacturing and commercialization of any lipid nanoparticle comprising product that
is licensed or optioned by Acuitas to a Third-Party or is under Late Stage Development by Acuitas. If Acuitas does not take steps to defend within a commercially reasonable time, or elects not to continue any such defense (in which case it will
promptly provide notice thereof to GreenLight), then GreenLight shall have the right, but not the obligation, to defend any Acuitas Patents that cover a Licensed Product and no other product licensed or optioned by Acuitas to a Third-Party or
commercialized by Acuitas provided that GreenLight shall bear all the expenses of such suit. 

  
 19 

 (ii) In the event that any action, suit or proceeding is brought against either
Party or an Affiliate of either Party, or a Sublicensee of GreenLight or its Affiliates, alleging the infringement of the Patents or Know-How of a Third-Party by the research, development, manufacture, use,
sale, import, export, commercialization or exploitation of a Licensed Product, such Party shall promptly notify the other Party within five (5) business days of the earlier of (x) receipt of service of process in such action, suit or
proceeding, or (y) the date such Party becomes aware that such action, suit or proceeding has been instituted. 
 (iii) (For
clarity, GreenLight shall have the sole right to defend any Patents owned or controlled by GreenLight, other than (for avoidance of doubt) the LNP Technology Patents or Joint Patents. 

(c) Response to Infringement Claims. Notwithstanding the foregoing, any response to a Third-Party infringer’s
counterclaim of invalidity or unenforceability of any LNP Technology Patents shall be controlled by the Party who controls the relevant enforcement proceeding pursuant to Section 7.2(a) unless otherwise mutually agreed by the Parties. 

(d) Withdrawal, Cooperation and Participation. With respect to any infringement or defensive action
regarding Acuitas Patents identified above in this Section 7.2: 
 (i) The
non-controlling Party will cooperate with the Party controlling any such action (as may be reasonably requested by the controlling Party), including by (A) providing access to relevant documents and other
evidence, (B) making its and its Affiliates and Sublicensees and all of their respective employees, subcontractors, consultants and agents available at reasonable business hours and for reasonable periods of time, but only to the extent
relevant to such action, and (C) if necessary, being joined as a party, subject for this clause (C) to the controlling Party agreeing to indemnify such non-controlling Party for its involvement as a
named party in such action and paying those Losses incurred by such Party in connection with such joinder. The Party controlling any such action will keep the other Party updated with respect to any such action, including providing copies of all
documents received or filed in connection with any such action. 

  
 20 

 (ii) Each Party will have the right to participate or otherwise be involved in any
such action controlled by the other Party, in each case at the participating (i.e., non-controlling) Party’s sole cost and expense. If a Party elects to so participate or be involved, the controlling
Party will provide the participating Party and its counsel with an opportunity to consult with the controlling Party and its counsel regarding the prosecution of such action (including reviewing the contents of any correspondence, legal papers or
other documents related thereto), and the controlling Party will take into account reasonable requests of the participating Party regarding such enforcement or defense. 

(e) Settlement. Neither Party will settle or consent to an adverse judgment in any action which affects the scope,
validity or enforcement of any LNP Technology Patents involved therewith, without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed); provided, that this Section 7.2(e) shall not
apply to the extent that such settlement or consent to an adverse judgment does not relate to an LNP Technology Patent. 
 (f)
Damages. Unless otherwise agreed by the Parties, all monies recovered upon the final judgment or settlement of any action which may be controlled by either GreenLight or Acuitas and described in Section 7.2(a) or 7.2(b) in each
case will be used first to reimburse the controlling Party, and thereafter the non-controlling Party, for each of their
out-of-pocket costs and expenses relating to the action, with the balance of any such recovery to be divided as follows: 

(i) To the extent such recovery reflects lost profits damages or a reasonable royalty with respect to Licensed Products, GreenLight
will retain such lost profits recovery, less the amount of Royalties payable to Acuitas by treating such lost profits recovery as “Net Sales” hereunder; and 

(ii) Any other recovery based on Licensed Products will be allocated seventy-five percent (75%) to the Party controlling the action
and twenty-five percent (25%) to the other Party; provided, that if such action is controlled by GreenLight and does not relate to an LNP Technology Patent or a Joint Patent then any other recovery will be allocated one hundred percent (100%) to
GreenLight. 
 ARTICLE 8 

Confidentiality 

8.1 Confidential Information. Each Party (“Disclosing Party”) may disclose to the other Party
(“Receiving Party”) and Receiving Party may acquire during the course and conduct of activities under this License Agreement, certain proprietary or confidential information of Disclosing Party in connection with this License
Agreement. The term “Confidential Information” means all Confidential Information as defined in or disclosed pursuant to the 

  
 21 

 
Development and Option Agreement, the terms of this Agreement, and all information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as
confidential or proprietary, that is disclosed or made available by or on behalf of the Disclosing Party to or on behalf of the Receiving Party in connection with this License Agreement. 

8.2 Restrictions. During the Term and for ten (10) years [or for so long as any trade secret has value derived from
its confidentiality if longer than ten (10) years] thereafter, or with respect to any trade secret included in the Confidential Information for so long as such trade secret is protected under applicable Laws (provided, that Receiving Party has
not publicly disclosed such trade secret in breach of its obligations under this Article 8), Receiving Party will keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party holds
its own confidential information, but in no event less than reasonable care. Receiving Party will not use Disclosing Party’s Confidential Information except in connection with the performance of its obligations and exercise of its rights under
this License Agreement. Receiving Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent to Receiving Party’s Affiliates, and each of their employees,
subcontractors, consultants and agents, in each case who have a need to know such Confidential Information in order to perform their obligations under and exercise their rights under this License Agreement and who are under written obligation to
comply with the restrictions on use and disclosure that are no less restrictive than those set forth in this Section 8.2. Receiving Party assumes responsibility for such entities and persons maintaining Disclosing Party’s Confidential
Information in confidence and using same only for the purposes described herein. 
 8.3
Exceptions. Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the Disclosing Party’s Confidential Information will not apply to a specific portion of the Disclosing Party’s
Confidential Information to the extent that Receiving Party can demonstrate that such portion: (a) was known to Receiving Party or any of its Affiliates prior to the time of disclosure by the Disclosing Party without obligation of
confidentiality; (b) is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates; (c) is obtained on a non-confidential basis by Receiving Party or any of
its Affiliates from a Third-Party who is lawfully in possession thereof and under no obligation of confidentiality to Disclosing Party; or (d) has been independently developed by or on behalf of Receiving Party or any of its Affiliates without
the aid, application or use of Disclosing Party’s Confidential Information as evidenced by written records. 
 8.4
Permitted Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the extent (and only to the extent) such disclosure is permitted under Section 8.2 or is reasonably necessary in the following
instances: 
 (a) in order and to the extent required to comply with applicable Laws (including any securities Laws or
regulations or the rules of a securities exchange applicable to Receiving Party) or with orders in connection with a legal or administrative proceeding; 

(b) in connection with litigation between the Parties; 

  
 22 

 (c) in connection with filing, prosecuting and enforcing LNP Technology
Patents in connection with Receiving Party’s rights and obligations pursuant to this License Agreement; 
 (d) to
acquirers, subject to Section 11.11, or permitted assignees, investment bankers, investors and lenders, including pursuant to a bona fide diligence review by potential acquirers, assignees, investment bankers, investors and lenders; and

 (e) in the case of GreenLight, to (i) Permitted Subcontractors, (ii) licensees, Sublicensees, assignees and
collaboration partners, or (iii) potential subcontractors, licensees, Sublicensees, assignees or collaboration partners, but in case (iii) only such information that is reasonably necessary or useful for the potential licensee,
Sublicensee, assignee or collaboration partner to evaluate the Licensed Product and LNP/Licensed Product manufacturing processes; provided, that (1) where reasonably possible, Receiving Party will notify Disclosing Party of Receiving
Party’s intent to make any disclosure pursuant to subsection (a) sufficiently prior to making such disclosure so as to assist and allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the
confidentiality of the information to be disclosed, including obtaining an adequate protective order, and (2) with respect to subsections (c) and (d), each of those entities are required to comply with the restrictions on use and
disclosure in Section 8.2 (other than investment bankers, investors and lenders, which must be bound prior to disclosure by commercially reasonable obligations of confidentiality). 

8.5 Return of Confidential Information. Upon expiry or earlier termination of this
License Agreement, each Party will destroy or return (as shall be specified by the other Party) to the other Party all copies of the Confidential Information of the other Party; provided, that a Party may retain: (a) one copy of such
Confidential Information for record-keeping purposes, for the sole purpose of ensuring compliance with this License Agreement; (b) any copies of such Confidential Information as is required to be retained under applicable Laws; (c) any
copies of such Confidential Information as are necessary or useful for such Party to exercise a right or fulfill an obligation hereunder; and (c) any copies of any computer records and files containing Confidential Information that have been
created by such Party’s routine archiving/backup procedures, in each case provided that such copies are maintained in accordance with this Article 8. 

8.6 Publications. Notwithstanding anything in this License Agreement to the contrary, only GreenLight is permitted
to publish the results of its development under this License Agreement, provided, however, that it will not disclose Acuitas Confidential Information (as defined in the Development and Option Agreement) in any publication by GreenLight of the
results of any Licensed Product development by GreenLight without Acuitas’ prior written consent, which will not be unreasonably withheld, conditioned or delayed. GreenLight will comply with standard academic practice regarding authorship of
scientific publications and recognition of the contributions of other parties in any scientific publications. 
 
8.7 Terms of this License Agreement; Publicity. The Parties agree that the existence and terms of the Parties’ relationship and this License Agreement will be treated as Confidential Information of both Parties, and thus may be
disclosed only as permitted by Sections 8.2 or 8.4. Except as required by applicable Laws (including any securities Laws or the regulations or rules 

  
 23 

 
of a securities exchange) or otherwise agreed by the Parties in writing, each Party agrees not to issue any press release or public statement disclosing information relating to the existence of
this License Agreement or the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party. 

ARTICLE 9 

Warranties; Limitations of Liability; Indemnification 

9.1 Representations and Warranties. Each Party represents and warrants to the other as
of the License Agreement Effective Date that: 
 (a) it is a corporation duly organized, validly existing, and in good standing
under the Laws of the jurisdiction in which it is incorporated, 
 (b) it has the legal right and power to enter into this
License Agreement, to extend the rights and licenses granted or to be granted to the other in this License Agreement, and to fully perform its obligations hereunder, 

(c) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this License
Agreement and the performance of its obligations hereunder, 
 (d) this License Agreement has been duly executed and delivered
on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, 

(e) the execution, delivery and performance of this License Agreement by such Party does not violate any Law of any court,
governmental body or administrative or other agency having jurisdiction over such Party, and 
 (f) no government
authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is
necessary for the transactions contemplated by this License Agreement or for the performance of its obligations under this License Agreement. 

9.2 Additional Representations of Acuitas. Except as set forth on Appendix 9.2, Acuitas hereby represents and
warrants to GreenLight as of the License Agreement Effective Date as follows: 
 (a) Impairment. Neither Acuitas
nor any of its Affiliates has entered into as of the Effective Date any agreement or otherwise licensed, granted, assigned, transferred, conveyed or otherwise encumbered or disposed of any right, title or interest in or to any of its assets,
including any Technology, that would in any way conflict with or impair the scope of any rights or licenses granted to GreenLight hereunder. . 

  
 24 

 (b) Patents and
Know-How. Appendix 1.40 sets forth a complete and accurate list of all LNP Technology Patents . Acuitas Controls, and will Control during the Term, the Licensed Technology, and is entitled to
grant the licenses specified herein. All Acuitas inventors of the Licensed Technology have validly assigned their rights to the Licensed Technology to Acuitas. To Acuitas’ knowledge, the LNP Technology Patents have been diligently prosecuted
and maintained in accordance with applicable Laws. None of the LNP Technology Patents are or have been involved in any opposition, cancellation, interference, reissue or reexamination proceeding, and to Acuitas’ knowledge as of the License
Agreement Effective Date, no Licensed Technology is the subject of any judicial, administrative or arbitral order, award, decree, injunction, lawsuit, proceeding or stipulation. As of the License Agreement Effective Date, neither Acuitas nor any of
its Affiliates has received any notice alleging that the LNP Technology Patents are invalid or unenforceable or challenging Acuitas’ ownership of or right to use the Licensed Technology. 

(c) Entire LNP Technology. The Acuitas Technology licensed to GreenLight under this License Agreement
comprises all LNP Technology owned or Controlled by Acuitas. 
 (d) Encumbrances. Acuitas and its Affiliates are
not subject to any payment obligations to Third Parties as a result of the execution or performance of this License Agreement. As of the License Agreement Effective Date, neither Acuitas nor any of its Affiliates has granted any liens or security
interests on the Licensed Technology, and the Licensed Technology as licensed hereby is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind. 

(e) Defaults. The execution, delivery and performance by Acuitas of this License Agreement and the
consummation of the transactions contemplated hereby will not result in any violation of, conflict with, result in a breach of or constitute a default under any understanding, contract or agreement to which Acuitas is a party or by which it is
bound, in each case as would reasonably be expected to have an adverse effect on the rights granted to GreenLight hereunder. 

(f) Litigation. There is no action, suit, proceeding or investigation pending or, to the knowledge of
Acuitas, currently threatened in writing against or affecting Acuitas that questions the validity of this License Agreement, the right of Acuitas to enter into this License Agreement or consummate the transactions contemplated hereby or that relates
to the Licensed Technology. 
 (g) Infringement. Neither Acuitas nor any of its Affiliates has received any
notice of any claim, nor does Acuitas or its Affiliates have any knowledge of any reasonable basis for any claim, that any Patent, Know-How or other intellectual property owned or controlled by a Third-Party
would be infringed or misappropriated by the practice of any Licensed Technology in connection with the production, use, research, development, manufacture or commercialization of any Licensed Product. . 

(h) Third-Party Infringement. To Acuitas’ knowledge, no Third-Party is infringing or has infringed any Patent
within the Licensed Technology or is misappropriating or has misappropriated any Know-How within the Licensed Technology. 

  
 25 

 9.3 Disclaimers. Without limiting the
respective rights and obligations of the Parties expressly set forth herein, each Party specifically disclaims any guarantee that any Licensed Product will be successful, in whole or in part. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS LICENSE
AGREEMENT, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTY OF ANY KIND UNDER THIS LICENSE AGREEMENT, EITHER EXPRESS OR IMPLIED. 

9.4 No Consequential Damages. NOTWITHSTANDING ANYTHING IN THIS LICENSE AGREEMENT OR OTHERWISE, NEITHER PARTY WILL BE
LIABLE TO THE OTHER OR ANY THIRD-PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS LICENSE AGREEMENT FOR ANY INDIRECT, PUNITIVE, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES; PROVIDED THAT THIS SECTION 9.4 WILL NOT APPLY TO BREACHES OF A PARTY’S
OBLIGATIONS UNDER ARTICLE 8 OR THE PARTIES’ INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER SECTION 9.6. 

9.5 Performance by Others. The Parties recognize that each Party may perform some or
all of its obligations under this License Agreement through Affiliates and Third-Party agents provided, however, that each Party will remain responsible and liable for the performance by its Affiliates and Third-Party agents and will cause its
Affiliates and Third-Party agents to comply with the applicable provisions of this License Agreement in connection therewith. 

9.6 Indemnification. 

(a) Indemnification by GreenLight. GreenLight will indemnify Acuitas, its Affiliates and their respective
directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, “Acuitas Indemnitees”), and defend and hold each of them harmless, from and against any and all losses, damages,
liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively,
“Third-Party Claims”) against the Acuitas Indemnitees to the extent arising from or occurring as a result of: (i) the breach by GreenLight of any provision of this License Agreement; (ii) any negligence or willful
misconduct on the part of any GreenLight Indemnitee in connection with this Agreement; or (iii) the development or commercialization by or on behalf of GreenLight or any of its Affiliates or Sublicensees of Licensed Products other than if
related to a Licensed Technology component thereof, except in each case (i)-(iii) to the extent Acuitas is obligated to indemnify GreenLight in accordance with Section 9.6(b) of this License Agreement. 

(b) Indemnification by Acuitas. Acuitas will indemnify GreenLight, its Affiliates, its Sublicensees and their
respective directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, “GreenLight Indemnitees”), and defend and hold each of them harmless, from and against any and all Losses in
connection with any and all Third-Party Claims against GreenLight Indemnitees to the extent arising from or occurring as a result of: (i) the breach by Acuitas of any provision of this License Agreement; or (ii) any negligence or willful
misconduct on the part of any Acuitas Indemnitee in connection with this Agreement; except in each case (i)-(ii) to the extent GreenLight is obligated to indemnify Acuitas in accordance with Section 9.6(a) of this License Agreement. 

  
 26 

 (c) Notice of Claim. All indemnification claims provided for in
Sections 9.6(a) and 9.6(b) will be made solely by such Party to this License Agreement (the “Indemnified Party”). The Indemnified Party will promptly notify the Indemnifying Party (the “Indemnifying Party”) in
writing of any Losses or the discovery of any fact upon which the Indemnified Party intends to base a request for indemnification under Section 9.6(a) and 9.6(b) (each such notice, an “Indemnification Claim Notice”), provided
that the failure to promptly provide such notice and details shall not relieve the Indemnifying Party of any of its indemnification obligations hereunder except to the extent that the Indemnifying Party’s defense of the relevant Third-Party
Claim is prejudiced by such failure. Each Indemnification Claim Notice must contain a description of the claim and the nature and estimated amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The
Indemnified Party will furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses and Third-Party Claims. 

(d) Defense, Settlement, Cooperation and Expenses. 

(i) Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third-Party Claim by giving
written notice to the Indemnified Party within thirty (30) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a Third-Party Claim, the Indemnifying Party may appoint as lead counsel
in the defense of the Third-Party Claim any legal counsel selected by the Indemnifying Party (the Indemnifying Party will consult with the Indemnified Party with respect to such counsel and a possible conflict of interest of such counsel retained by
the Indemnifying Party). In the event the Indemnifying Party assumes the defense of a Third-Party Claim, the Indemnified Party will immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by
the Indemnified Party in connection with the Third-Party Claim. 
 (ii) Right to Participate in Defense.
Without limiting Section 9.6(d)(i), any Indemnified Party will be entitled to participate in, but not control, the defense of such Third-Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment
will be at the Indemnified Party’s own cost and expense unless (A) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 9.6(d)(i) (in which case the Indemnified Party will control the
defense), (B) the Indemnifying Party is not diligently defending the interests of both Parties, or (C) the interests of the Indemnified Party and the Indemnifying Party with respect to such Third-Party Claim are sufficiently adverse to prohibit
the representation by the same counsel of both Parties under applicable Law, ethical rules or equitable principles, in which case the Indemnifying Party will assume one hundred percent (100%) of any such costs and expenses of counsel for the
Indemnified Party. 
 (iii) Settlement. With respect to any Third-Party Claims that relate solely to the payment of
money damages in connection with a Third-Party Claim and that will not (A) result in the Indemnified Party’s becoming subject to injunctive or other relief, (B) include any admission or concession of liability or wrongdoing on the
part of the Indemnified Party, or (C) otherwise adversely affect the business of the Indemnified Party in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnified Party
hereunder, the Indemnifying Party will have the sole right to agree to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the 

  
 27 

 
Indemnifying Party, in its sole discretion, will deem appropriate, provided that such settlement or other disposition results in a complete release of all such Third-Party Claims. With respect to
all other Losses in connection with Third-Party Claims, where the Indemnifying Party has assumed the defense of the Third-Party Claim in accordance with Section 9.6(d)(i), the Indemnifying Party will have authority to agree to the entry of any
judgment, enter into any settlement or otherwise dispose of such Loss only if it obtains the prior written consent of the Indemnified Party (such consent not to be unreasonably withheld, delayed or conditioned). The Indemnifying Party will not be
liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached without the prior written consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third-Party
Claim, no Indemnified Party will admit any liability with respect to or settle, compromise or discharge, any Third-Party Claim without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, delayed or
conditioned. 
 (iv) Cooperation. Regardless of whether the Indemnifying Party chooses to defend or prosecute any
Third-Party Claim, the Indemnified Party will, and will cause each other Indemnified Party to, cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such
conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith, at the Indemnifying Party’s expense. Such cooperation will include access during normal business hours afforded to the
Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third-Party Claim, and making Indemnified Parties and other employees and agents available on a mutually
convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket costs and expenses in connection therewith. 
 (v) Costs and
Expenses. Except as provided above in this Section 9.6(d), the costs and expenses, including attorneys’ fees and expenses, incurred by the Indemnified Party in connection with any claim will be reimbursed on a Calendar Quarter
basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to prompt refund in the event the Indemnifying Party is ultimately held not to be
obligated to indemnify the Indemnified Party. 
 9.7 Insurance. Each Party will
maintain at its sole cost and expense, an adequate liability insurance or self-insurance program (including product liability insurance) to protect against potential liabilities and risk arising out of activities to be performed under this License
Agreement and upon such terms (including coverages, deductible limits and self-insured retentions) as are customary in the respective industry of such Party for the activities to be conducted by such Party under this License Agreement. Subject to
the preceding sentence, such liability insurance or self-insurance program will insure against all types of liability, including personal injury, physical injury or property damage arising out of the manufacture, sale, use, distribution or marketing
of Licensed Products. The coverage limits set forth herein will not create any limitation on a Party’s liability to the other under this License Agreement. Upon the request of a Party, the other Party will provide evidence of the insurance
coverage required by this Section 9.7. 

  
 28 

 ARTICLE 10 

Term and Termination 

10.1 Term. This License Agreement will commence as of the License Agreement Effective
Date and, unless sooner terminated in accordance with the terms hereof or by mutual written consent, will continue on a Licensed Product-by-Licensed Product and a country-by-country basis, until there are no more Royalty payments owed Acuitas in such country with respect to such Licensed Product (the longest such period of time
hereunder, the “Term”). Upon expiration of the Term with respect to the applicable Licensed Product in the applicable country, the licenses contained in Section 2.1 will become fully
paid-up, royalty-free, perpetual and irrevocable with respect to such Licensed Product in such country. 

10.2 Termination by Acuitas. 

(a) Breach. Acuitas will have the right to terminate this License Agreement in full upon delivery of written
notice to GreenLight in the event of a material breach by GreenLight of this License Agreement, provided that such material breach has not been cured within sixty (60) days after written notice thereof is given by Acuitas to GreenLight
specifying the nature of the alleged breach. 
 (b) Disputed Breach. If GreenLight disputes in good faith the
existence or materiality of a breach specified in a notice provided in accordance with Section 10.2(a), and GreenLight provides Acuitas notice of such dispute within such sixty (60) day period, then Acuitas shall not have the right to
terminate this License Agreement under Section 10.2(a) unless and until it is finally determined, in accordance with Section 11.1, that GreenLight has materially breached this License Agreement and GreenLight has failed to cure such breach
within sixty (60) days following such decision. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this License Agreement shall remain in effect and the Parties shall continue to perform all
of their respective obligations hereunder. During the pendency of any such dispute, GreenLight shall pay to Acuitas all Milestone Payments and Royalty payments set forth herein that may become due during such period. 

10.3 Termination by GreenLight. 

(a) Breach. GreenLight will have the right to terminate this License Agreement in full upon delivery of written
notice to Acuitas in the event of a material breach by Acuitas of its obligations under this License Agreement, provided that such breach has not been cured within sixty (60) days after written notice thereof is given by GreenLight to Acuitas
specifying the nature of the alleged breach 
 (b) Discretionary Termination. GreenLight will have the right to
terminate this License Agreement in full at its discretion for any reason by delivering written notice to Acuitas, such termination to be effective thirty (30) days following the date of such notice. 

(c) Alternative to Termination Under Section 10.3(a). 

(i) If GreenLight has the right to terminate this License Agreement under Section 10.3(a), then GreenLight may, in lieu of
exercising such termination right, elect to have this License Agreement continue in full force and effect, provided that the following will apply: starting immediately after the end of such applicable cure period, GreenLight may reduce by [***] the
Milestone Payments and the Royalty rates subject to the Minimum Royalty. 

  
 29 

 (ii) In the event Acuitas notifies GreenLight within thirty (30) days of
receipt of GreenLight’s notice of material breach that Acuitas reasonably and in good faith disputes GreenLight’s right to terminate this License Agreement pursuant to Section 10.3(a), GreenLight shall instead deposit such [***] of
Milestone Payments and Royalty payments into an escrow account maintained by a mutually agreeable Third-Party pending the resolution of such dispute in accordance with Section 11.1. If Acuitas raises such dispute, the informal dispute
resolution process in Section 11.1(a) shall not apply, and the negotiation period for the Executive Officers in Section 11.1(b) shall be limited to ten (10) days. 

(iii) In the event that it is established through the dispute resolution process that GreenLight did have the right to terminate this
License Agreement under Section 10.3(a), then the escrowed funds shall be released to GreenLight and the [***] reduction shall continue to apply going forward. In the event that it is established through the dispute resolution process that
GreenLight did not have the right to terminate this License Agreement under Section 10.3(a), then the escrowed funds plus interest payable by GreenLight in accordance with Section 4.4(g) shall be released to GreenLight and GreenLight will
pay to Acuitas the full amount of the Milestone Payments and Royalties that would have been payable, and the Milestone Payments and the Royalty payments going forward shall continue to be paid in accordance with Article 4 and the terms of this
Agreement without any reduction under this Section 10.3(c). 
 10.4 Termination Upon Bankruptcy. If either Party
makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition or commences a proceeding under any bankruptcy or insolvency act in any state
or country or has any such petition or application filed against it which is not discharged within one hundred twenty (120) days of the filing thereof, then the other Party may thereafter terminate this License Agreement effective immediately
upon written notice to such Party. All rights and licenses granted under or pursuant to this License Agreement by Acuitas are, and will otherwise be deemed to be, for purposes of Section 65.11(7) of the Bankruptcy and Insolvency Act, R.S.C.
1985, c. B-3 and Section 32(6) of the Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36, and comparable laws in other jurisdictions (the
“Insolvency Legislation”), a grant of “right to use intellectual property” as used in the Insolvency Legislation. The Parties agree that GreenLight and its Affiliates and Sublicensees, as licensees of such rights under
this License Agreement, will retain and may fully exercise all of their rights and elections under the Insolvency Legislation subject to the payment of amounts provided for herein. Without limiting GreenLight’s rights under the Insolvency
Legislation, if Acuitas becomes insolvent or makes an assignment for the benefit of its creditors or there is filed by or against Acuitas any bankruptcy, receivership, reorganization or similar proceeding pursuant to or under the Insolvency
Legislation or otherwise, GreenLight shall be entitled to a copy of any and all such intellectual property and all embodiments of such intellectual property, and the same, if not in the possession of Acuitas, shall be promptly delivered to it
(a) before this License Agreement is disclaimed, repudiated, rescinded or terminated by or on behalf of Acuitas, within thirty (30) days after GreenLight’s written request, unless Acuitas, or its trustee or receiver, elects within
thirty (30) days to continue to perform all of its obligations under this 

  
 30 

 
License Agreement, or (b) after any disclaimer, repudiation, rescission or termination of this License Agreement by or on behalf of Acuitas, if not previously delivered as provided under
clause (a) above. All rights of the Parties under this Section 10.4 and under the Insolvency Legislation are in addition to and not in substitution of any and all other rights, powers, and remedies that each Party may have under this
License Agreement, the Insolvency Legislation, and any other applicable Laws. 
 10.5 Effects of Termination. Upon termination (but
not expiration of the Term pursuant to Section 10.1) of this License Agreement for any reason: 
 (a) Cessation of
Rights. Except as otherwise expressly provided herein, all rights and licenses granted by Acuitas to GreenLight in Section will terminate. 

(b) Sell Off. Notwithstanding the termination of GreenLight’s licenses and other rights under this
License Agreement, GreenLight shall retain the right to distribute, sell or otherwise dispose of its existing inventory of the Licensed Products, in each case that is intended for distribution, sale or disposition in the Territory, for a period of
not more than three (3) months following the date of the effective termination, as though this License Agreement had not been terminated, and such distribution, sale or other disposition shall not constitute infringement of the Patents or other
intellectual property or proprietary rights of Acuitas or its Affiliates. GreenLight’s right to distribute, sell or otherwise dispose of its existing inventory of the Licensed Products pursuant to this Section 10.5(b) shall be subject to
GreenLight’s continuing obligation to pay Royalties with respect to the Net Sales. 
 10.6 Survival. In
addition to the termination consequences set forth in Section 10.5, the following provisions will survive termination or expiration of this License Agreement: Article 1 (to the extent applicable to any other surviving provisions), Article 3,
Article 5, Article 8 and Article 11, and Sections 2.1 (in accordance with (i) the last sentence of Section 4.4(d), to the extent applicable, (ii) Section 6.2, to the extent applicable, or (iii) the last sentence of
Section 10.1 but only upon expiration of the Term), 2.3(b)(iv) (only upon the circumstances set forth therein), 4.4(b), 9.3, 9.4, 9.5, 9.6, the last sentence of Section 10.1 (only upon expiration of the Term), 10.4, 10.5 and this
Section 10.6. Termination or expiration of this License Agreement will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from
pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this License Agreement nor prejudice either Party’s right to obtain performance of any obligation. All other rights and obligations will
terminate upon termination or expiration of this License Agreement. 
 ARTICLE 11 

General Provisions 

11.1 Dispute Resolution. 

(a) Disputes. Disputes arising under or in connection with this License Agreement will be resolved pursuant to
this Section 11.1; provided, however, that in the event a dispute cannot be resolved without an adjudication of the rights or obligations of a Third-Party (other than any GreenLight Indemnitees or Acuitas Indemnitees identified in
Section 9.6), the dispute procedures set forth Sections 11.1(b) and 11.1(c) will be inapplicable as to such dispute. 

  
 31 

 (b) Dispute Escalation. In the event of a dispute between the
Parties, the Parties will first attempt in good faith to resolve such dispute by negotiation and consultation between themselves or the Workplan Leaders. In the event that such dispute is not resolved on an informal basis within twenty
(20) days, any Party may, by written notice to the other, have such 
 (c) dispute referred to each Party’s Chief
Executive Officer or his or her designee (who will be a senior executive “Executive Officers”), who will attempt in good faith to resolve such dispute by negotiation and consultation for a thirty (30) day period following receipt of
such written notice. 
 (d) Dispute Resolution. In the event the Executive Officers of the Parties are not able
to resolve such dispute as set forth above, the Executive Officers will together elect whether to submit the dispute to mediation, litigation or arbitration. In the absence of such an agreement, either Party may elect to initiate litigation. The
Parties hereby irrevocably and unconditionally consent to submit to the exclusive jurisdiction of the state and federal courts located in the State of Washington for any disputes, including for (1) interim or provisional relief or
(2) breaches of Article 6 or Article 7 for which the Parties agree injunctive relief or equitable remedies will be available arising out of or relating to this Agreement, and further agree that service of any process, summons, notice or
document by certified mail shall be effective service of process for any action, suit or proceeding brought against the Parties in any such court. The Parties hereby irrevocably and unconditionally waive any objection to the laying of venue of any
action, suit or proceeding arising out of this Agreement in the state or federal courts located in the State of Washington and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such
action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 
 (e) Injunctive
Relief. Notwithstanding the dispute resolution procedures set forth in this Section 11.1, in the event of an actual or threatened breach hereunder, the aggrieved Party may seek equitable relief (including restraining orders, specific
performance or other injunctive relief) in any court or other forum, without first submitting to any dispute resolution procedures hereunder. 

(f) Prevailing Party. The prevailing Party in any suit related to this License Agreement will be entitled to
recover from the losing Party all out-of-pocket fees, costs and expenses (including those of attorneys, professionals and accountants and all those arising from appeals
and investigations) incurred by the prevailing Party in connection with such arbitration or suit. 
 11.2 Cumulative
Remedies and Irreparable Harm. All rights and remedies of the Parties hereunder will be cumulative and in addition to all other rights and remedies provided hereunder or available by agreement, at Law or otherwise. Each Party acknowledges
and agrees that breach of any of the terms or conditions of this License Agreement may cause irreparable harm and damage to the other and that such damage may not be ascertainable in money damages and that as a result thereof the non-breaching Party may be entitled to seek from a court equitable or injunctive relief restraining any breach or future violation of the terms contained herein by the breaching Party without the necessity of
proving actual damages or posting bond. Such right to equitable relief is in addition to whatever remedies either Party may be entitled to as a matter of Law or equity, including money damages. 

  
 32 

 11.3 Relationship of Parties. Nothing in this License Agreement is intended or will
be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. No Party will incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided therein.
There are no express or implied Third-Party beneficiaries hereunder (except for GreenLight Indemnitees and Acuitas Indemnitees for purposes of Section 9.6). For clarity, GreenLight does not grant to Acuitas any rights or licenses under this
License Agreement to any GreenLight Technology or intellectual property rights. 
 11.4 Compliance with Law.
Each Party will perform or cause to be performed any and all of its obligations or the exercise of any and all of its rights hereunder in good scientific manner and in compliance with all applicable Law, including the U.S. Foreign Corrupt Practices
Act and foreign equivalents thereof. Without limiting the foregoing, each Party agrees that it has not, and covenants that it, its Affiliates, and its and its Affiliates’ directors, employees, officers, and anyone acting on its behalf, will
not, in connection with the performance of this Agreement, directly or indirectly, make, promise, authorize, ratify or offer to make, or take any action in furtherance of, any payment or transfer of anything of value for the purpose or intent of
influencing, inducing or rewarding any act, omission or decision to secure an improper advantage; or improperly assisting it in obtaining or retaining business for it or the other Party, or in any way with the purpose or effect of public or
commercial bribery. 
 11.5 Governing Law. This License Agreement will be governed by and construed in accordance with the Laws of
the State of New York, United States, without respect to its conflict of Laws rules in the event of a dispute in accordance with Section 11.1, provided that any dispute relating to the scope, validity, enforceability or infringement of any
Patents or Know-How will be governed by, and construed and enforced in accordance with, the substantive Laws of the jurisdiction in which such Patents or Know-How apply.

 11.6 Counterparts; Facsimiles. This License Agreement may be executed in one or more counterparts, each of
which will be deemed an original, and all of which together will be deemed to be one and the same instrument. Facsimile or PDF execution and delivery of this License Agreement by either Party will constitute a legal, valid and binding execution and
delivery of this License Agreement by such Party. 
 11.7 Headings. All headings in this License Agreement are for convenience only and will
not affect the meaning of any provision hereof. 
 11.8 Waiver of Rule of Construction. Each Party has had the
opportunity to consult with counsel in connection with the review, drafting and negotiation of this License Agreement. Accordingly, the rule of construction that any ambiguity in this License Agreement will be construed against the drafting Party
will not apply. 

  
 33 

 11.9 Interpretation. Whenever any provision of this License Agreement uses the
term “including” (or “includes”), such term will be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,” “hereby,” “hereunder,”
“hereof” and other equivalent words refer to this License Agreement as an entirety and not solely to the particular portion of this License Agreement in which any such word is used. All definitions set forth herein will be deemed
applicable whether the words defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Appendices in this License Agreement are to Sections and Appendices of this License Agreement. References
to any Sections include Sections and subsections that are part of the related Section. 
 11.10 Binding Effect. This
License Agreement will inure to the benefit of and be binding upon the Parties, their Affiliates, and their respective lawful successors and assigns. 

11.11 Assignment. This License Agreement may not be assigned by either Party, nor may either Party delegate its obligations or
otherwise transfer licenses or other rights created by this License Agreement, except as expressly permitted hereunder or otherwise without the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned or
delayed; provided that either Party may assign this License Agreement without such consent to an Affiliate or to its successor in connection with the sale of all or substantially all of its assets or business or that portion of its business
pertaining to the subject matter of this License Agreement (whether by merger, consolidation or otherwise). 
 11.12
Notices. All notices, requests, demands and other communications required or permitted to be given pursuant to this License Agreement will be in writing and will be deemed to have been duly given upon the date of receipt if delivered
by hand, email, recognized international overnight courier, or registered or certified mail, return receipt requested, postage prepaid to the following addresses: 
  

					
		 	if to GreenLight:	  	GreenIight Biosciences Inc.
		 		  	Suite 3100
		 		  	200 Boston Avenue
		 		  	 Medford MA 02155
 Attention: [***]GLB CFO

[***]

			
		 	With a copy to:	  	 Foley Hoag LLP 
155 Seaport Blvd. 
Boston, MA 02110
  

Attention: [***]
 [***]

			
		 	 If to Acuitas:
	  	 Acuitas Therapeutics Inc.
 6190 Agronomy
Road
 Vancouver, B.C.
 V6T 1Z3

Attention: President and CEO
 [***]

  
 34 

					
		 	 With a copy to:
	  	 McCarthy Tetrault LLP
 Suite 2400 745 Thurlow
Street
 Vancouver, B.C.
 Canada V6E 0C5

Attention: [***].
 [***]

 Either Party may change its designated address by notice to the other Party in the manner provided in this
Section 11.12. 
 11.13 Amendment and Waiver. This License Agreement may be amended, supplemented, or otherwise modified only by
means of a written instrument signed by both Parties; provided that any unilateral undertaking or waiver made by one Party in favor of the other will be enforceable if undertaken in a writing duly executed by the Party to be charged with the
undertaking or waiver. Any waiver of any rights or failure to act in a specific instance will relate only to such instance and will not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

 11.14 Severability. In the event that any provision of this License Agreement will, for any reason, be held
to be invalid or unenforceable in any respect, such invalidity or unenforceability will not affect any other provision hereof, and the Parties will negotiate in good faith to modify the License Agreement to preserve (to the extent possible) their
original intent. 
 11.15 Entire Agreement. This License Agreement, together with the Development and Option Agreement, are the sole
agreements with respect to the subject matter hereof and supersede all other agreements and understandings between the Parties with respect to same subject matter. 

11.16 Force Majeure. Neither Acuitas nor GreenLight will be liable for failure of or delay in performing
obligations set forth in this License Agreement (other than any obligation to pay monies when due), and neither will be deemed in breach of such obligations, if such failure or delay is due to natural disasters or any unexpected causes reasonably
beyond the control of Acuitas or GreenLight that are unforeseeable; provided that the Party affected will promptly notify the other of the force majeure condition and will exert reasonable efforts to eliminate, cure or overcome any such causes and
to resume performance of its obligations as soon as possible. In the event it is not possible to resume performance within six (6) months, such failure or delay will be considered a material breach and subject to Sections 10.2(a) and 10.3(a).

 [Remainder of this Page Intentionally Left Blank] 

  
 35 

 WITNESS WHEREOF, the Parties have caused this
Non-Exclusive License Agreement to be executed by their respective duly authorized officers as of the License Agreement Effective Date. 

 

			
	 ACUITAS THERAPEUTICS,
INC.

			
		
	 By:
	 	 
		 	 (Signature)

			
	 Name:
	 	 

			
		
	 Title:
	 	 

			
		
	 Date:
	 	 

  

			
	GREENLIGHT BIOSCIENCES, INC.

			
		
	By:	 	 
		 	(Signature)

			
	Name:	 	 

			
		
	Title:	 	 

			
		
	Date:	 	 

  
 36 

 Appendix 1.38  

Licensed Product 
 [***] 

 [***] 

 [***] 

 Appendix 1.29 

Jointly Owned Patents 

 Appendix 1.40 

Patents within the Licensed Technology as of the License Agreement Effective Date 

 Appendix 9.2 

Exceptions to Acuitas’ Representations and Warranties in Section 9.2EX-10.24

 Exhibit 10.24 

Certain identified information has been omitted from this exhibit because it is 

not material and of the type that the registrant treats as private or confidential. 

[***] indicates that information has been omitted. 

ASSIGNMENT AND LICENSE AGREEMENT BETWEEN 

BAYER COMPANY AND GREENLIGHT BIOTECHNOLOGY, INC. 

This Agreement (“Agreement”) is made and entered into to be effective as of the Effective Date by and between Bayer CropScience
LLP, having its principal business offices at 800 North Lindbergh Boulevard, St. Louis, Missouri 63167, and GreenLight Biosciences, Inc. having its principal business offices at 200 Boston Ave. Suite 1000, Medford, MA 02155
(“GreenLight”). Bayer CropScience LLP and GreenLight Biosciences, Inc. may be referred to herein individually as a “Party”, or collectively as the “Parties”. 

BACKGROUND 
 NOW,
THEREFORE, in consideration of the premises and mutual covenants and agreements hereinafter set forth, the Parties agree as follows: 
  

	1.	 DEFINITIONS. 

For purposes of this Agreement, in addition to terms defined elsewhere herein, the following words and phrases will have the following
meanings: 
 1.1 “Affiliate” means any person, partnership, corporation, association, or other entity that, during the Term
of this Agreement, directly or indirectly Controls, is Controlled by, or is under common Control with, a particular Party, for so long as such Control is effective. 

1.2 “Bayer” means Bayer CropScience LLP and its Affiliates. 

1.3 “Bee Health Know-how” means information directed or related to the use of [***]
to control [***], wherein said information is/will be provided to Greenlight as follows: 
 (a) in the documents as provided in a secure
electronic data room and identified in Appendix A hereto, including: 
 (i) specifications, designs, materials sourcing information, and
material safety data sheets (MSDS) relevant to the pouches for delivering product comprising such [***] in or to [***], wherein said pouches are to be provided to GreenLight pursuant to Section 2.1.4; 

(ii) a detailed description of end-stage [***] methods, purity of the active ingredient, and
justifications for selected [***] values, and copies of or citations for any references relied upon by Bayer; 

 (iii) information regarding bee health product formulation(s), including composition
constituents and concentrations thereof; 
 (iv) information regarding the experimental designs high- and
low-dose studies; 
 (v) correspondence with regulatory authorities; 

(b) the identity and contact information of participants in Bayer’s bee health field trials that have expressed willingness to be
contacted by GreenLight to possibly participate in GreenLight’s bee health field trials provided according to Section 2.1.3.4; 

(c) information provided by Bayer according to Section 2.1.3.2 and Section 2.1.3.3; 

(d) specifications and designs relevant to packaging equipment for filling and processing said pouches, provided the Parties reach an
agreement for the purchase of said packaging equipment, which the Parties agree to negotiate in good faith within four (4) months of the Closing Date; 

(e) the 90-day docket report regarding the Bee Health Patents, copies of all outstanding Office
actions for the Bee Health Patents, and reasonable access to printable versions of the Bee Health Patents as provided by Bayer according to Section 7.1; wherein any information disclosed verbally by Bayer employees shall be memorialized in
writing, with reasonable specificity, by GreenLight and copies of the same shall be provided by GreenLight to Bayer no later than one month after the end of the Reasonable Access period. 

1.4 “Bee Health License” means all of Bayer’s rights in and to a license agreement between Bayer and Yissum Research and
Development Company of the Hebrew University of Jerusalem LTD (hereinafter “Yissum”), a copy of which has been viewable by GreenLight in a secured electronic data room and will be downloadable by the Closing Date. 

1.5 “Bee Health Patents” means the patents and patent applications identified as belonging to Bayer’s patent families
58862, 58864, 58865, 60216, 60220, 61478, and 62697, and more specifically identified in Appendix B hereto, and any continuations, continuation-in-part, divisionals,
reexaminations, or reissues thereof, and any foreign counterparts of the same or related PCT applications. 
 1.6 “Closing
Date” shall be December 10, 2020. 
 1.7 “Confidential Information” of a disclosing Party means (i) the
existence, terms, and conditions of this Agreement; (ii) any information or material in tangible form, disclosed by the disclosing Party that is marked as “Confidential” at the time it is delivered to the receiving Party; and
(iii) information or material disclosed orally by the disclosing Party that is identified as confidential or proprietary when disclosed and such disclosure 

 
of confidential information is confirmed in writing (or by facsimile or email) within thirty (30) days by the disclosing Party; and (iv) all information disclosed by the disclosing
Party prior to the Effective Date, including non-executed drafts prepared during the negotiation of this Agreement and the terms set forth therein; provided, however, that the above information will not
be deemed Confidential Information, to the extent the receiving Party can establish by a preponderance of the evidence that such information: 

(a) was already known to the receiving Party, other than under an obligation of confidentiality owed to the disclosing Party, at the time of
disclosure; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure hereunder to
the receiving Party; 
 (c) becomes generally available to the public or otherwise part of the public domain after its disclosure and other
than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was independently developed by the receiving
Party without use of or reference to any Confidential Information disclosed by the disclosing Party; or 
 (e) was subsequently disclosed
to the receiving Party by a person other than the disclosing Party, wherein said person was not under any legal obligation with the disclosing Party to refrain from disclosing such information to Third Parties at the time of the disclosure; 

(f) is expressly approved for release to the public by written authorization of the disclosing Party; or 

(g) is required to be disclosed by the receiving Party pursuant to a court order or as otherwise required by law. Confidential Information
that is specific in nature, which is disclosed by either Party will not be deemed within any exceptions set forth in (a)-(g), above, merely because it is embraced by more general information to which one or more of those exceptions may apply.
Further, any combination of features shall not be deemed to be within any exceptions set forth in (a)-(g), above, merely because individual features are in the public domain or in the possession of the receiving Party. 

1.8 “Control” or “Controlled” means: 

(a) as to Confidential Information or Intellectual Property that is licensed, the possession of the ability to grant licenses or sublicenses
(including, where applicable, as provided for herein) without violating the terms of any agreement or other arrangement with any Third Party; 

 (b) as to obtaining, maintaining, enforcing and/or defending Intellectual Property,
including the prosecution of patent applications, the maintenance of patent rights, and the enforcement and/or defense of patent rights, both inside and outside the United States, the authority to select legal counsel, solicit other expert advice
and assistance, and to make decisions pertaining to the conduct of patent prosecution, interferences, patent oppositions, patent 
 (c)
issuance, maintenance, reissue, reexamination, patent enforcement or defense, as applicable; and 
 (d) as to an entity, (i) ownership
of fifty percent (50%) or more in the aggregate of the voting power of all outstanding equity interest entitled to vote at a general election of directors of such entity, (ii) ownership of fifty percent (50%) or more of the equity interests in
such entity, or (iii) ownership of fifty percent (50%) or more of the assets of such entity. 
 1.9 “Delivery Patents”
means patents and patent applications identified as belonging to Bayer’s patent [***], and more specifically identified in Appendix C hereto, and any continuations,
continuation-in-part, divisionals, reexaminations, or reissues thereof, and any foreign counterparts of the same or related PCT applications. 

1.10 “Effective Date” shall be the date of the latest signature executing this Agreement. 

1.11 “Field” means the external application to a plant, a seed, or an arthropod plant pest of a [***] that causes induction
of [***] without genetic engineering of such targeted plant, seed, or arthropod plant pest. For the avoidance of doubt, the Field excludes, for example: 

(a) all human and animal (other than arthropods) therapeutic, prophylactic, and diagnostic applications; 

(b) modification of any cells, tissues, or organisms for the purpose of manufacturing heterologous proteins, peptides, or viruses for any
purpose, including producing therapeutic products; and 
 (c) genetic engineering of a plant, plant cell, or plant tissue to produce a
polynucleotide active agent that causes induction of RNA-dependent gene silencing. 
 1.12
“GreenLight” means GreenLight BioSciences, Inc. and each of its Affiliates. 
 1.13 [***] 

1.14 “Insect Control Know-how” means the information in the documents identified in
Appendix D hereto, including information regarding the control of [***]. 
 1.15 “Insect Control Patents” means the patents
and patent applications identified as belonging to Bayer’s patent families [***], and more specifically identified in Appendix E hereto, and any continuations,
continuation-in-part, divisionals, reexaminations, or reissues thereof, and any foreign counterparts of the same or related PCT applications. 

 1.16 “Intellectual Property” or “IP” means generally any
and all right, title, and interest in, arising from, or relating to inventions, discoveries, data, know-how, works of authorship and information, including copyrights, patents and patent applications, any
registrations or applications relating to any of the foregoing, and any other rights of a similar nature or character whether now existing or hereafter created, developed, arising or otherwise coming into being. 

1.17 “Official” means any appointed, elected, or honorary official or any career employee of the government of a foreign
country, or of a public international organization, or any political party, party official, or candidate in any foreign country. For purposes of this Agreement, the “government” includes any agency, department, embassy, or other
governmental entity of any foreign country, and any company or other entity owned or controlled by any of the foregoing. A person does not cease to be an Official by purporting to act in a private capacity or by the fact that he or she serves
without compensation. 
 1.18 “Reasonable Access” means the access period(s) beginning on the Closing Date, duration(s),
topic(s), and manner(s) of communication set forth for each person identified in Appendix F. 
 1.19 “Term” has the meaning
set forth in Section 11. 
 1.20 “Third Party” mean a person, partnership, corporation, association, or other entity
other than Bayer and GreenLight and their respective Affiliates. 
 1.21 “USD” means United States of America Dollars. 

 

	2.	 PURCHASE, ASSIGNMENT, AND LICENSES.  

2.1.1 Purchase and Assignment of Bee Health Patents. GreenLight agrees to purchase and Bayer agrees to sell, transfer, and assign its
entire right, title, and interest in and to the Bee Health Patents to GreenLight on the Closing Date for the consideration in Section 5 and GreenLight agrees to accept said assignment. 

2.1.1.1 Recordation document. Bayer and GreenLight will execute an assignment document identifying the Bee Health
Patents no later than the Closing Date, wherein said assignment document is intended to be suitable for recordation with each of the applicable patent offices. If such assignment document is not suitable for recordation Bayer agrees to cooperate
with GreenLight to cure any deficiencies in such assignment document necessary for recordation with the applicable patent offices. 
 2.1.2
Assignment of Bee Health License. Bayer hereby assigns and agrees to assign its entire right, title, and interest in and to the Bee Health License, and GreenLight hereby accepts said assignment and agrees to the terms and conditions of the
Bee Health License. 

 2.1.2.1 Yissum’s consent. Bayer shall work to provide to
GreenLight a copy of Yissum’s consent to the assignment of Bayer’s interest in and to the Bee Health License no later than the Closing Date. If such consent is not obtained by the Closing Date, Bayer shall continue to work secure the
consent after the Closing Date. 
 2.1.2.2 GreenLight’s acknowledgement. If requested by Bayer or Yissum,
GreenLight will acknowledge in writing that it agrees to the terms and conditions of the Bee Health License no later than the Closing Date. 

2.1.3 License of Bee Health Know-how. Bayer hereby grants to GreenLight, and GreenLight
accepts, sublicensable, worldwide, royalty-free license under the Bee Health Know-how to conduct research, develop, make, use, offer for sale, sell, import, or export methods and products directed to the
[***], wherein said license shall be co-exclusive with Bayer only from the Closing Date until the tenth (10th) anniversary of the Effective Date and non-exclusive thereafter for all purposes. 
 2.1.3.1 Access to Bee Health Know-how documents. Bayer shall provide to GreenLight copies of, or downloadable access to, the Bee Health Know-how documents no later than the Closing Date. 

2.1.3.2 Access to Bee Health Know-how via Bayer employees. Bayer shall provide
GreenLight Reasonable Access to Bayer’s employees set forth in Appendix F to disclose Bee Health Know-how to GreenLight. 

2.1.3.3 Access to Bee Health Know-how via former Bayer employee. [***]
will be a former Bayer employee as of January 1, 2021, and Bayer shall release him from his obligation of confidentiality to Bayer solely to disclose Bee Health Know-how to GreenLight. 

2.1.3.4 Access to field trial participants. Bayer will contact the participants in its bee health field trials and
determine which of said participants are willing to be contacted by GreenLight to participate in its bee health field trials. As indicated in Section 1.3(b), Bayer will disclose the identity and contact information of such willing participants
to GreenLight no later than thirty (30) days after the Closing Date. 
 2.1.4 Access to pouches. Bayer shall provide to
GreenLight approximately [***] pouches believed to be suitable for delivering product comprising [***] within one month after the Closing Date. 

2.1.5 No other licenses. This Agreement does not grant, expressly or impliedly, GreenLight any rights in, to, or under the Bee Health Know-how, except those expressly recited in Section 2.1.3 and Section 2.1.4. 

 2.1.6 License to Insect Control Patents. Subject to Bayer’s reserved rights set
forth in Section 2.2.3, Bayer hereby grants to GreenLight, and GreenLight accepts, an exclusive, sublicensable, worldwide, royalty-free license under the Insect Control Patents to conduct research, develop, make, use, offer for sale, sell,
import, or export methods and products in the Field from the Closing Date until the expiration of the last to expire of the Insect Control Patents. 

2.1.7 License to Insect Control Know-how. Bayer hereby grants to GreenLight, and GreenLight
accepts, a sublicensable, non-exclusive, worldwide, royalty-free license under the Insect Control Know-how to make, use, offer for sale, sell, import, or export methods
and products in the Field. 
 2.1.7.1 Access to Insect Control Know-how
documents. Bayer shall provide to GreenLight copies of, or downloadable access to, the Insect Control Know-how documents no later than the Closing Date. 

2.1.8 Reservation of research rights in the Field. Bayer hereby reserves non-sublicensable,
worldwide, non-exclusive rights under the Insect Control Patents to make, use, import, and export, but not sell or offer for sale, methods and products in the Field. 

2.1.9 No other licenses. This Agreement does not grant, expressly or impliedly, GreenLight any rights in, to, or under the Insect
Control Patents or the Insect Control Know-how, except those expressly recited in Section 2.2.1 and Section 2.2.2. For example, in addition to Section 2.2.3, Bayer retains exclusive rights in,
to, and under the Insect Control Patents and Insect Control Know-how for use outside the Field, including, for example, [***] that may be covered by one or more claims of the Insect Control Patents. 

2.1.10 License to Delivery Patents. Bayer hereby grants to GreenLight, and GreenLight accepts, a
non-exclusive, non-sublicensable, worldwide, royalty-free license under the Delivery Patents to make, use, offer for sale, sell, import, or export methods and products:

 (a) for the topical application to [***] and/or 

(b) in the Field. 
 2.1.11
No other licenses. This Agreement does not grant, expressly or impliedly, GreenLight any rights in, to, or under the Delivery Patents, except those expressly recited in Section 2.3.1. 

 

	3.	 EXCLUSIVITY AND COMPETITIVE ACTIVITIES.  

3.1 Limited disclosure of certain Bee Health Know-how. Bayer will take commercially reasonable
efforts to refrain from disclosing Bee Health Know-how to GreenLight Competitors during the period beginning with the Effective Date and ending on the tenth (10th) anniversary of the Effective Date, unless
required by law, regulation, or order. 

 3.2 Status regarding Bayer’s development of certain insect control products.
[***]. 
 3.3 Bayer’s commercialization of [***]. [***]. 

3.4 Bayer’s commercialization of Bee Health products. To the extent allowable under applicable antitrust law, which shall be
determined in Bayer’s sole discretion, Bayer will refrain from selling or offering for sale a method or product directed to the [***] during the period beginning with the Effective Date and ending on the tenth (10th) anniversary of the
Effective Date. 
  

	4.	 DILIGENCE. 

4.1 GreenLight’s commercialization of Bee Health products. GreenLight will use commercially reasonable efforts to develop and sell
a method or product directed to the [***]. GreenLight shall disclose an executive summary of such efforts with projected completion dates for the milestones set forth in Sections 5.2 and 5.3 in annual reports due on June 30th of each year until
payment of the First Sale Milestone Fee as set forth in Section 5.3 
  

	5.	 FINANCIAL TERMS. 

5.1 Initial Fee. In exchange for the assignments and licenses set forth in Section 2, and in addition to other consideration set
forth herein, GreenLight shall pay to Bayer a fee of [***] USD ([***]USD) on the Closing Date (the “Initial Fee”). 
 5.2 EPA
Registration Milestone Fee. In exchange for the assignments and licenses set forth in Section 2, and in addition to other consideration set forth herein, GreenLight shall pay to Bayer a fee of [***] USD ($[***]USD) no later than one month
after receiving the first U.S. EPA registration for the [***] (the “EPA Registration Milestone Fee”). Within one week after receiving said first U.S. EPA registration, GreenLight shall notify Bayer of the same. 

5.3 First Sale Milestone Fee. In exchange for the assignments and licenses set forth in Section 2, and in addition to other
consideration set forth herein, GreenLight shall pay to Bayer a fee of [***] USD ([***]USD) no later than one month after the first U.S. sale of a [***] (the “First Sale Milestone Fee”). Within one week after said first U.S. sale of a
[***], GreenLight shall notify Bayer of the same. 
  

	6.	 PAYMENTS. 

6.1 Payment Method. All payments due under this Agreement will be made by bank wire transfer in immediately available funds or by
Electronic Funds Transfer (EFT) in funds available in 5-7 business days to the following bank account: 

[***] 

 All payments hereunder will be made in USD. If the due date of any payment is a Saturday, Sunday or national
holiday, such payment may be paid on the following business day. 
 6.2 Tax Matters. All payments required pursuant to this Agreement
will be paid net of any deduction therefrom for withholding for or on account of any tax, fee, levy, assessment or other governmental charge imposed upon such payments by any jurisdiction. The withholding Party will provide the other Party with a
certificate evidencing payment of any such withholding taxes pursuant to this Section 6.2. 
 6.3 Interest. All payment required
pursuant to this Agreement will, if overdue, bear interest until payment at a per annum rate two percent (2%) above the prime rate quoted in the Money Rates section of The Wall Street Journal, Eastern Edition for the date on which payment was due,
calculated daily on the basis of a 365-day year; provided, however, that in no event will such rate exceed the maximum legal annual interest rate. 

 

	7.	 INTELLECTUAL PROPERTY.  

7.1 Responsibility for patents and associated costs and expenses. Beginning on the Closing Date, GreenLight shall be responsible for all
decisions regarding, and costs and expenses associated with prosecuting, maintaining, defending, and enforcing the Bee Health Patents. As such, GreenLight shall reimburse Bayer for any such costs and expenses incurred with respect thereof that may
be invoiced to Bayer until such time as GreenLight is established as the owner or applicant with the relevant foreign and domestic patent attorneys and agents and patent offices. Before the Closing Date, Bayer shall provide GreenLight a docket
report for the Bee Health Patents that, among other things, identifies all action items until 90 days after the Closing Date. Additionally, Bayer shall provide GreenLight copies of all outstanding Office actions for the Bee Health Patents having a
response deadline during said 90-day period. Also, Bayer will provide GreenLight reasonable access to printable versions of the Bee Health Patents. Further, promptly after the Closing Date, Bayer will notify
all legal counsel responsible for prosecuting and maintaining the Bee Health Patents of the transfer of Bayer’s entire interest in the Bee Health Patents to GreenLight and will identify GreenLight’s contact information as designated by
GreenLight and said legal counsel of Bayer will provide the prosecution history files of the Bee Health Patents to GreenLight or the legal counsel designated by GreenLight. 

This Agreement does not alter Bayer’s responsibility for all decisions regarding, and costs and expenses associated with prosecuting, maintaining,
defending, and enforcing the Insect Control Patents and the Delivery Patents. 

 7.2 Abandonment of licensed patents. If Bayer elects to stop prosecuting or
maintaining any Insect Control Patents before issuance or expiration, respectively, Bayer will give GreenLight notice thereof at least sixty (60) days prior to allowing such patents or patent applications to lapse or become abandoned; except in
situations in which the patent office procedure provides for a shorter deadline or communications to Bayer from its outside legal counsel and results in less than sixty (60) days notice, in which case Bayer will give GreenLight reasonable
notice before lapse or abandonment. If requested by GreenLight, Bayer will assign the same to GreenLight subject to GreenLight granting Bayer a non-exclusive,
non-sublicensable, royalty/payment-free license under such patent/application and any subsequently filed patent/application claiming priority thereto until such application(s) or patent(s) are abandoned,
lapsed, or expired. Upon such an assignment, GreenLight shall be responsible for all decisions regarding, and costs and expenses associated with prosecuting, maintaining, defending, and enforcing such application(s) and patent(s). 

 

	8.	 CONFIDENTIALITY. 

8.1 Confidential Information. Except as expressly provided in this Agreement, the Parties agree that, for the Term of this Agreement
plus five (5) years or a period of ten (10) years after the initial disclosure, whichever is earlier, the receiving Party will keep completely confidential and will not publish or otherwise disclose and will not use for any purpose except
for the purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing Party hereto pursuant to this Agreement. Without limiting any provision of this Agreement, each of the Parties hereto will be responsible
for the observance by its employees of the confidentiality obligations set forth in this Section 8 and this Agreement, generally. If either Party becomes aware or has knowledge of any unauthorized use or disclosure of the other Party’s
Confidential Information, it will promptly notify the other Party of such unauthorized use or disclosure. 
 Notwithstanding any provision in this Agreement
to the contrary, even upon expiration of the above-described period of confidentiality, although GreenLight may disclose Confidential Information contained in documents provided hereunder by Bayer, GreenLight shall use its best efforts to refrain
from providing copies (physical or electronic) of said documents or excerpts therefrom attributed to Bayer. 
 8.2 Permitted
Disclosures. Except as otherwise limited by this Agreement, each Party hereto may disclose the other Party’s Confidential Information only in the following circumstances: 

(a) A Party may disclose Confidential Information of the other Party, or to its advisors, collaborators, financial investors or acquirers,
including prospective financial investors, acquirers or Affiliates, and the agents or advisors of the foregoing and other similarly situated Third Parties, on a need to know basis, if such permitted recipients agree to be bound by the terms of this
Section 8 or have a fiduciary duty of confidentiality; 
 (b) A Party may disclose, to the extent such disclosure is reasonably
necessary, Confidential Information of the other Party in connection with: 

 (i) filing or prosecuting patent applications (provided that neither Party will file any
patent application claiming any invention conceived by the other Party except as expressly authorized by this Agreement), prosecuting or defending litigation; and/or 

(ii) complying with applicable governmental laws and regulations or judicial order, or otherwise submitting information to taxing or other
governmental authorities; provided that in case (i) and/or (ii) if a Party is required to make any such disclosure of another Party’s Confidential Information, other than pursuant to a confidentiality agreement, it will give
reasonable advance notice to the latter Party of such disclosure and save in the case of patent applications will cooperate with the original disclosing Party in any effort by the original disclosing Party to secure a protective order or other
remedy affording confidential treatment of such Confidential Information and/or waive compliance with confidentiality provisions of this Agreement; 

(c) A Party may disclose, to the extent such disclosure is reasonably necessary, the existence of this Agreement to the United States
Securities and Exchange Commission or any securities exchange or other securities trading institution (if a copy of this Agreement has to be submitted, the Parties will agree upon an appropriately redacted version of this Agreement for submission);
and 
 (d) A Party may disclose Confidential Information of the other Party in a public disclosure that is mutually agreed upon by the
Parties in accordance with Section 8.3. 
 In the event that a protective order or other remedy is not obtained, or that the disclosing Party waives
compliance with the provisions hereof, the receiving Party so requested or compelled agrees to furnish only that portion of the disclosing Party’s Confidential Information that it is advised by counsel is legally required to be disclosed and to
exercise reasonable efforts to obtain assurance that confidential treatment will be accorded the Confidential Information. 
 8.3 Press
Release or Public Disclosure. The Parties will agree upon a press release or equivalent public disclosure to announce the execution of this Agreement no later than February 15, 2021, together with a corresponding Q&A outline for use in
responding to inquiries about this Agreement and/or the Parties’ relationship; thereafter, GreenLight and Bayer may each disclose to Third Parties the information contained in such press release or public disclosure and Q&A outline without
the need for further approval by the other. 
  

	9.	 REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMERS.  

9.1 Representations and warranties of GreenLight. GreenLight represents and warrants to Bayer that the statements contained in this
Section 9.1 are correct and complete as of the Effective Date. 
 9.1.1 Organization. GreenLight is a duly organized and validly
existing corporation in good standing under the laws of the state of Delaware and has the power and authority to own, lease and operate its assets and properties and to conduct its business as now being conducted. 

 9.1.2 Authorization. There is no provision in GreenLight’s articles of
organization or in its operating agreement which prohibits or limits the ability of GreenLight to consummate the transactions contemplated hereby. GreenLight has the full right, power and authority to enter into this Agreement and to consummate or
cause to be consummated all of the transactions contemplated hereby and to fulfill or cause to be fulfilled all of the obligations of GreenLight hereunder. The execution and delivery of this Agreement by GreenLight and the due consummation by
GreenLight of the transactions contemplated hereby have been duly authorized by all necessary action of the Board of Directors of GreenLight. This Agreement constitutes a legal, valid and binding agreement of GreenLight enforceable against
GreenLight in accordance with its terms. 
 9.1.3 Consents and approvals. No consent or approval from any Third Party is required to
be made or obtained by GreenLight in connection with the execution, delivery and performance of this Agreement, or the consummation of the transactions contemplated hereby. 

9.1.4 No conflict or violation. Neither the execution, delivery or performance of this Agreement, nor the consummation of the
transactions contemplated hereby will result in a breach of, or a default under, any term or provision of any contract, agreement, indebtedness, lease, encumbrance, commitment, license, franchise, permit, authorization or concession to which
GreenLight is a party. 
 9.2 Representations and warranties of Bayer. Bayer represents and warrants to GreenLight that the
statements contained in this Section 9.2 are correct and complete as of the Effective Date. 
 9.2.1 Organization. Bayer is a
duly organized and validly existing corporation in good standing under the laws of the state of Delaware and has the power and authority to own, lease and operate its assets and properties and to conduct its business as now being conducted. 

9.2.2 Authorization. There is no provision in Bayer’s articles or certificate of incorporation or in its bylaws which prohibits or
limits Bayer’s ability to consummate the transactions hereby. Bayer has the full right, power and authority to enter into this Agreement and to consummate or cause to be consummated all of the transactions contemplated hereby and to fulfill or
cause to be fulfilled all of the obligations of Bayer hereunder. The execution and delivery of this Agreement by Bayer and the due consummation by Bayer of the transactions contemplated hereby have been duly authorized by all necessary action of the
board of directors of Bayer. This Agreement constitutes a legal, valid and binding agreement of Bayer enforceable against Bayer in accordance with its terms. 

 9.2.3 Consents and approvals. Other than as disclosed herein, no consent or approval
from any Third Party is required to be made or obtained by Bayer in connection with the execution, delivery and performance of this Agreement, or the consummation of the transactions contemplated hereby and thereby. 

9.2.4 No conflict or violation. Neither the execution, delivery or performance of this Agreement, nor the consummation of the
transactions contemplated hereby or thereby will result in a breach of, or a default under, any term or provision of any contract, agreement, indebtedness, lease, encumbrance, commitment, license, franchise, permit, authorization or concession to
which Bayer is a party. 
 9.2.5 No adverse effect on the assigned or licensed assets. Bayer represents that to its knowledge the
assignment and licenses granted to GreenLight pursuant to this Agreement will not have a materially adverse effect on any of the Bee Health Patents, Bee Health Know-how, Insect Control Patents, Insect Control Know-how, or Delivery Patents. 
 9.2.6 No pre-existing grants
to the assigned or exclusively licensed assets. Bayer represents that it has not granted a Third Party any rights in and to the Bee Health Patents, Bee Health Know-how, or the Insect Control Patents that
are in contravention of, or in conflict with, the rights granted in the same to GreenLight pursuant to this Agreement. 
 9.2.7 Ownership
of Bee Health Patents. Until completion of the closing on the Closing Date, Bayer possesses either a partial ownership interest in and to, or the entire right, title, and interest in and to the Bee Health Patents and its interests therein
(partial or entire) are free and clear of any security interest, license, or other restrictions. 
 9.2.8 No known violations of the duty
of candor to the USPTO regarding Bee Health Patents. As of the Effective Date, Bayer’s IP counsel responsible for managing the Bee Health Patents does not have actual knowledge of: 

(a) any public use, sale, sale, printed publication, or other non-confidential disclosure by Bayer of
any invention claimed in a U.S. Bee Health Patent having Docket Number 60216 US 0001 or 60216 US 00002 prior to the effective filing date of said U.S. Bee Health Patent; nor 

(b) any violation of the duty to disclose information material to patentability set forth in 37 C.F.R. § 1.56 by Bayer for (i) any
U.S. Bee Health Patent having Docket Number 60216 US 0001, 60216 US 0002, 60216 US 0003, 60220 US 0002, or 61478 US 0001 and (ii) any U.S. Bee Health Patent having Docket Number 58862 US 0001, 58862 US 0002, 58862 US 0003, 58864 US 0001, 58864
US 0002, 58864 US 0003 58865 US 0001, or 58865 US 0002 as of the date of Bayer’s acquisition of said U.S. Bee Health Patent. 
 9.2.9
No known actions alleging invalidity of Bee Health Patents. Bayer has no actual knowledge of an action, suit, or proceeding before any court, quasi-judicial or administrate agency of the U.S. or a foreign jurisdiction that could result in a
decision, judgment, order, or ruling that a Bee Health Patent is invalid. 

 9.3 Compliance with laws. 

9.3.1 General representations. Each Party represents and warrants that it will take no action in relation to this Agreement that would
be in violation of, or would subject the other Party to any liability or penalty under, the applicable laws and regulations of any foreign country and the United States of America. 

9.3.2 9.3.2. Representations regarding Officials. Each Party represents and warrants as of the Effective Date that none of its
officers, directors, or employees who are currently expected to work on or communicate about the matters covered by this contract is an Official and that no Official is directly or indirectly a principal owner or investor in the Party and that no
Official has any substantial financial interest in the contractual relationship established by this Agreement and that the Party will not interact with any Officials on behalf of the other Party in any activities contemplated by this Agreement. 

9.3.3 No improper payments. Each Party represents and warrants that no payments of money or anything of value will be offered, promised
or paid, directly or indirectly, to any Officials to influence the acts of such Officials to induce them to use their influence with a government or an instrumentality thereof, or to obtain an improper advantage in connection with any business
venture or contract in which the other Party is a participant. 
 9.4 Disclaimer of warranties. Except as expressly provided in
Sections 3.2, 9.1, 9.2, and 9.3, GreenLight and Bayer each expressly disclaim any warranties, including any implied warranties of merchantability, patentability, non-infringement, fitness for a particular
purpose, or any warranty that any patent assigned or licensed hereunder will be valid or enforceable. Each Party acknowledges that it is not relying on any warranties other than those set forth in Sections 3.2, 9.1, 9.2, and 9.3. 

 

	10.	 LIMITATIONS OF LIABILITY AND INDEMNIFICATION.  

10.1 Notice; Defense. In the event that Bayer receives notice of any Third Party claim, action or proceeding for which Bayer (the
“Indemnitee”) claims indemnity hereunder, the Indemnitee will promptly notify GreenLight (the “Indemnitor”) of such matter. The Indemnitor will then promptly assume responsibility for and will have full control of such matter,
including settlement negotiations and any legal proceedings, and the Indemnitee will fully cooperate at the Indemnitor’s expense in the Indemnitor’s handling and defense thereof. The Indemnitee may participate, at its own expense, in the
defense of such claim or litigation provided that the Indemnitor will direct and control the defense of such claim or litigation. The Indemnitor will not, in the defense of such claim or litigation resulting therefrom, consent to entry of any
judgment except with the written consent of the Indemnitee, which will not be unreasonably withheld, or enter into any settlement except with the written consent of the Indemnitee, which will not be unreasonably withheld, which: (i) does not
include as an unconditional term thereof the giving by the plaintiff to the Indemnitee of a release from all liability in respect of such claim or litigation; or (ii) contains any admission of liability. 

 10.2 Limitation of GreenLight’s liability. SUBJECT TO AND WITHOUT MITIGATION OF
GREENLIGHT’S OBLIGATIONS OF INDEMNIFICATION UNDER SECTION 10.3, EXCEPT IN THE EVENT OF GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, GREENLIGHT, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, AND AFFILIATES WILL NOT BE LIABLE TO BAYER FOR INCIDENTAL,
SPECIAL, EXEMPLARY, CONSEQUENTIAL, INDIRECT OR PUNITIVE DAMAGES OF ANY KIND, INCLUDING LOST PROFITS, LOST OR DIMINISHED PRODUCTION, BUSINESS INTERRUPTION OR CLAIMS OF CUSTOMERS OR OTHER THIRD PARTIES, WHETHER OR NOT GREENLIGHT HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES, AND WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE. 

10.3 Indemnification. GreenLight will defend, indemnify and hold harmless Bayer, including its Affiliates, and its and their directors,
officers, employees, agents and representatives from and against any damages, liabilities, losses, costs and expenses (including reasonable attorneys’ fees, court costs and other costs) arising from fines, civil penalties, personal injury to,
or damage to the property of Third Parties (including for purposes of this Section 10.3 the employees of the Parties) to the extent such damages, liabilities, losses, costs and expenses are directly caused by GreenLight’s
(a) recklessness, willful misconduct, violation of law, or breach of any representations or warranties in this Agreement, or (b) activities conducted using, or resulting from, or covered by the
know-how and patents assigned or licensed under this Agreement. 
 10.3.1 Notice; Defense. In
the event that Bayer receives notice of any Third Party claim, action or proceeding for which Bayer (the “Indemnitee”) claims indemnity hereunder, the Indemnitee will promptly notify GreenLight (the “Indemnitor”) of such matter.
The Indemnitor will then promptly assume responsibility for and will have full control of such matter, including settlement negotiations and any legal proceedings, and the Indemnitee will fully cooperate at the Indemnitor’s expense in the
Indemnitor’s handling and defense thereof. The Indemnitee may participate, at its own expense, in the defense of such claim or litigation provided that the Indemnitor will direct and control the defense of such claim or litigation. The
Indemnitor will not, in the defense of such claim or litigation resulting therefrom, consent to entry of any judgment except with the written consent of the Indemnitee, which will not be unreasonably withheld, or enter into any settlement except
with the written consent of the Indemnitee, which will not be unreasonably withheld, which: (i) does not include as an unconditional term thereof the giving by the plaintiff to the Indemnitee of a release from all liability in respect of such
claim or litigation; or (ii) contains any admission of liability. 

	11.	 TERM AND TERMINATION.  

11.1 Term. The term of this Agreement will commence on the Effective Date and will continue until the expiration of the last to expire
of all patents and patent applications owned or Controlled by a Party that are licensed hereunder to the other Party unless terminated early pursuant to the remaining subsections of Section 11 or any other relevant provisions set forth in this
Agreement (the “Term”). Without limiting the foregoing, the Term will survive the non-renewal or termination of any particular license hereunder, subject to the terms of this Agreement. Additionally,
the Parties agree that to the extent any of the licenses granted under this Agreement are to an invention, data, know-how, and/or work of authorship that is Confidential Information at the end of the Term of
this Agreement (unless terminated early pursuant to the remaining subsections of Section 11 or any other relevant provisions set forth in this Agreement), said licenses will continue, without royalty or any other obligations under this
Agreement, save the confidentiality provisions under Section 8, until such time as the same are no longer are subject to the confidentiality provisions due to the passage of time pursuant to Section 8.1. 

Additionally, notwithstanding any provision of this Agreement to the contrary, neither expiration or termination of this Agreement by Bayer releases
GreenLight from its obligations to pay the EPA Registration Milestone Fee and the First Sale Milestone Fee under Sections 5.2 and 5.3, respectively. 

11.2 Termination “For Cause”. Either Party may, upon written notice to the other Party, terminate this Agreement if the other
Party has materially breached this Agreement and failed to cure such material breach within sixty (60) days after receiving written notice thereof from the Party seeking to terminate. A termination under this Section 11.2 will be effective
only if the Party seeking to terminate provides notice of breach, such breach is not cured within sixty (60) days, and such Party then provides written notice of termination upon expiration of such cure period. 

11.3 Termination of Licenses for Patent Challenge. In the event that GreenLight directly or indirectly: 

(a) issues a press release, public announcement, news release alleging invalidity or unenforceability of any claim of the Insect Control
Patents or Delivery Patents; or 
 (b) asserts a claim or counterclaim in the courts seeking to invalidate or render unenforceable any
claim of the Insect Control Patents or Delivery Patents; or 
 (c) assists another Third Party with either or both (a) or (b); wherein
each of (a), (b), or (c) is a “Challenge Event” and each of GreenLight and its Affiliates is a “Challenger”, then Challenger shall provide reasonable written notice but in no event less than sixty
(60) days written notice to Bayer prior to initiating such a Challenge Event, along with a copy of any prior art, if known, that forms the basis for the Challenge Event. 

 Upon the occurrence of a Challenge Event, Bayer shall have the right, but not the obligation, to immediately
terminate GreenLight’s licenses to the Insect Control Patents and the Delivery Patents. 
 To be clear, a dispute involving determinations of claim
scope or construction does not constitute challenging or denying the validity or enforceability of any of the Insect Control Patents or the Delivery Patents is not a Challenge Event unless a Challenger actually contests the validity, enforceability,
and/or requests reexamination of or opposes a patent or contests the allowance or issuance of a patent application licensed. Also, challenging or denying the validity or enforceability of any of the Insect Control Patents or Delivery Patents does
not include provoking or participating in an interference proceeding. 
 11.3.1 Forum of a Challenge Event. GreenLight agrees on
behalf of itself and every other Challenger that it/they shall bring or assist in bringing a Challenge Event seeking to invalidate or render unenforceable any claim of the U.S. Insect Control Patents and the Delivery Patents only in the U.S.
District Court for the Eastern District of Missouri, and not to contest personal jurisdiction in that forum. If this foregoing forum selection clause is determined by the court to not prohibit a Challenger from bringing or assisting in bringing a
Challenge Event before an applicable governmental agency (e.g., the United States Patent Trial and Appeal Board), then category (b) of the Challenge Event also includes asserting invalidity or unenforceability of any claim of the U.S. Insect
Control Patents and the Delivery Patents before an applicable governmental agency. 
 11.3.2 Compensation. Moreover, should the
outcome of any such action or proceeding be unsuccessful, the Challenger(s) shall pay Bayer’s costs, expenses, and reasonable attorneys’ fees incurred in such action. An action or proceeding shall be deemed “unsuccessful” for
purposes of this Section 11.3 if: 
 (i) the proceeding or lawsuit is terminated for any reason prior to a settlement or judgment from
which no appeal can be or is taken; 
 (ii) one or more of the claims within the patents challenged by said proceeding or lawsuit remain
valid and enforceable after any such settlement or judgment is in effect; or 
 (iii) if one or more Challengers would still require a
license to any of the Insect Control Patents or Delivery Patents to make, have made, offer sale, sell, or use any of its products after any such settlement or judgment is in effect. 

11.4 Effects of Agreement Termination. Upon termination of this Agreement by Bayer, all licenses granted to GreenLight will terminate,
and GreenLight will promptly: (a) cease any all uses of Bee Health Know-how, and Insect Control Know-how (some or all of which may be Bayer Confidential Information
and subject certain provisions of this Agreement, including Section 11.6); and (b) cease all activities that would be an infringement of a patent licensed hereunder. 

11.5 Accrued Obligations. Termination of this Agreement for any reason will not release any Party from any obligations that, at the
time of such termination, has already accrued to the other Party or any obligations that, by their nature, will continue, including those set forth in this Section 11 and Sections 5, 6, 8, 9, 10, and 12. 

 11.6 Return or Destruction of Confidential Information. Upon any termination of this
Agreement, each Party will return to the other Party or destroy all Confidential Information of the other Party then in its possession or control, except to the extent such Confidential Information of the other Party is reasonably necessary to such
Party’s exercise of its surviving rights under this Agreement. Notwithstanding the foregoing, the receiving Party shall not be obligated to delete electronic copies of Confidential Information stored in archival
back-ups created in the ordinary course of business so long as the archival back-ups are maintained in confidence and are not readily accessible to users. Each Party
will continue to be bound by the terms of this Agreement with respect to any and all Confidential Information of the other Party that is not returned to the other Party or destroyed. 

 

	12.	 MISCELLANEOUS. 

12.1 Construction and interpretation. All terms defined in the singular form will include the plural and vice versa. Unless otherwise
stated, all sections referred to herein are sections of this Agreement. Each of the exhibits, schedules and appendices referred to in this Agreement and attached hereto, and all attachments and amendments thereto, are and will be incorporated herein
and made a part hereof. But in the event any such exhibits, schedules, or appendices, or portions thereof are contrary to the terms and conditions of this Agreement, the terms and conditions of this Agreement will prevail. The headings of the
articles and sections in this Agreement are inserted for convenience only and are not intended to interpret, define or limit the scope or content hereof or any provision hereof. The word “including” will not be construed as limiting the
immediately preceding general term or statement. 
 12.2 Choice of law. This Agreement will be governed by and construed in
accordance with the laws of the State of Delaware, U.S.A. (unless the Parties agree in writing otherwise) without giving effect to the choice of law provisions thereof which will be disregarded in their entirety; provided that all questions
concerning the construction or effect of patent applications and patents will be decided in accordance with the laws of the country in which the particular patent application or patent concerned has been filed or granted, as the case may be. 

12.3 Severability. If any term, condition or provision of this Agreement or the application thereof is judicially or otherwise
determined to be invalid or unenforceable, or if the Parties mutually agree in writing to any revision of this Agreement, the remainder of this Agreement and the application thereof will not be affected, except to the extent of any such revision,
and this Agreement will otherwise remain in full force and effect. If the absence of any term, condition or provision of this Agreement that has been judicially or otherwise determined to be invalid or unenforceable causes a material adverse change
in either the risks or benefits of this Agreement to either Party, then the Parties will negotiate in good faith a commercially reasonable substitute or replacement for the invalid or unenforceable provision. 

 12.4 Rights. Except for the rights expressly provided for in this Agreement, no right
or license to any information, materials, inventions, or know-how provided by either Party to the other is granted or implied. 

12.5 Assignment and succession. This Agreement and the licenses granted herein are not assignable or transferable by, or subject to
succession from, GreenLight to any Third Party without the prior written consent of Bayer; provided, however, such consent will not be unreasonably withheld in connection with a change of Control of GreenLight. The terms and conditions of
this Agreement will be binding on and inure to the benefit of the permitted successors, transferees, and assigns of the Parties. Any attempted assignment, transfer, or succession in violation of this Section 12.5 will be null and void. 

12.6 Waiver of default. No waiver of any default by either Party will be deemed to constitute a waiver of any subsequent default with
respect to the same or any other provision hereof. No waiver will be effective unless made in writing with specific reference to the relevant provision of this Agreement and signed by a duly authorized representative of the Party granting the
waiver. 
 12.7 Non-Solicitation. GreenLight agrees that, during the Term, GreenLight shall
not, directly or indirectly solicit or induce, or attempt to solicit or induce, any employee, distributor, sales representative, agent or contractor of Bayer to whom GreenLight is given Reasonable Access as well as [***] to leave Bayer for any
reason whatsoever, or hire any such person, except for [***]. Notwithstanding the foregoing, you shall be entitled to place public advertising and any response received by you to any such public advertising or subsequent hirings resulting
therefrom shall not be considered as a breach of this Section 12.7 as long as you did not otherwise breach your obligations under this Section 12.7 in connection with such public advertising. 

12.8 Relationship of Parties. Nothing contained in this Agreement is intended implicitly, or is to be construed, to constitute Bayer
and GreenLight as partners in the legal sense. The Parties are independent contractors, and no agency, franchise, joint venture, employment or other similar relationship is intended or created by this Agreement. No Party hereto will have any express
or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party. 

12.9 Compliance with law. Each Party will comply with all applicable governmental laws, rules and regulations in the performance of its
obligations under this Agreement. 
 12.10 Force Majeure. Either Party may suspend performance of any of its obligations under this
Agreement, in whole or in part, without liability to the other Party by promptly notifying the other Party of the nature and estimated duration of the suspension period in the event of: act of God, war, riot, fire, explosion, terrorist action,
accident, lack of adequate fuel, power, compliance with governmental requests, laws, regulations, orders or actions, breakage or failure of machinery or apparatus, national 

 
defense requirements or any other event, whether or not of the classes enumerated herein, beyond the reasonable control of the Party, or in the event of labor trouble, strike, lockout or
injunction (provided that neither Party will be required to settle a labor dispute against its own best judgment), which event renders the performance of the obligation commercially impracticable. The
non-performing Party will correct or remove the conditions creating the force majeure event within sixty (60) days, or if such conditions cannot reasonably be corrected or removed within such sixty
(60) day period, then the non-performing Party will work diligently to correct or remove such conditions within such sixty (60) days and will complete such correction or removal within one hundred
and twenty (120) days (or such longer period of time reasonably required to correct or remove a curable condition) after the force majeure event. If the corrections or removal of the conditions creating the force majeure event are not completed
within such one hundred and twenty (120) day period (or such longer period of time reasonably required to correct or remove a curable condition) by the non-performing Party, then the other Party will have
the right to terminate this Agreement without penalty. 
 12.11 Entire Agreement. This Agreement constitutes the entire agreement
between the Parties relating to the subject matter hereof. All prior agreements or arrangements, written or oral, between the Parties relating to the subject matter hereof are hereby superseded and merged with this Agreement. This Agreement may not
be modified except in writing signed by both Parties. 
 12.12 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one single agreement between the Parties. Signatures via facsimile or other electronic means are deemed to be the same as original signatures.

 12.13 Notices. All notices and other communications required or permitted under this Agreement shall be deemed to be properly
given when in writing, which shall include communications by electronic means (i.e., an electronic transmission), and shall be effective: when delivered, if delivered by hand or reputable courier service; five (5) days after mailing, if mailed
by registered or certified mail, postage prepaid and return receipt requested; or on the date sent, if dispatched by electronic transmission; addressed to each Party at the following addresses or such other address as may be designated by notice
pursuant to this: 
 If to Bayer: 

Bayer Crop Science LLP 
 800 North
Lindbergh Boulevard 
 St. Louis, Missouri 63167 

Attn.: [***], MNC Relationships and Trait Licensing 

w/email to: [***] 
 w/copy
of any notice relating to breach or termination to: 
 Bayer Crop Science LLP 

800 North Lindbergh Boulevard 

St. Louis, Missouri 63167 
 Attn.:
[***], US Law Intellectual Property & Licensing Lead 
 w/ email to: [***] 

 If to GreenLight Biosciences, Inc.: 

GreenLight Biosciences, Inc. 
 200
Boston Ave, Suite 1000 
 Medford, MA 02155 

Attn.: [***] 
 w/ email to:
[***] 
 w/copy of any notice relating to breach or termination to: 

GreenLight Biosciences, Inc. 
 200
Boston Ave, Suite 1000 
 Medford, MA 02155 

Attn.: [***] 
 w/ email to:
[***] 
 Either Party may use for electronic transmission the DocuSign® online document
delivery and signature service of Third Party vendor DocuSign, Inc., or such other method of electronic transmission as to which the Parties agree from time to time. 

Each Party will be required to provide and maintain an operable address(es) of an electronic nature through which the specified manner of electronic
transmission can be accomplished. Such address may be changed by a Party upon notice by hand, courier or mail as described above, or upon notice by electronic transmission. 

Notwithstanding that any notice given by electronic transmission is effective on the date of dispatch, a recipient may be required to give acknowledgement of
receipt of notice by electronic transmission; provided that the effective date of the notice shall remain as the date of dispatch, not the time of acknowledgement; and further provided that failure of a recipient to acknowledge receipt shall not
affect the effectiveness of the notice. 
 12.14 Further assurances. The Parties will execute and deliver such further documents and
do such further acts and things, including amending this Agreement, as may be required to carry out the intent and purpose of this Agreement. 

12.15 Legal Fees and costs. Except as otherwise provided herein, all legal and other costs and expenses incurred in connection with
this Agreement and the transactions contemplated hereby are to be paid by the Party incurring such costs and expenses. 
 12.16
Language. All written materials, correspondence, technical information, notices and oral assistance supplied by either Party hereto will be in the English language. 

 12.17 Third Party beneficiary. This Agreement is solely for the benefit of the
Parties and their respective successors and permitted assigns, and no other person or entity has any right, benefit, priority or interest under or because of the existence of this Agreement. 

12.18 Advice of counsel. GreenLight and Bayer each consulted counsel of their choice regarding this Agreement, and each acknowledges
and agrees that this Agreement will not be deemed to have been drafted by one Party or another and will be construed accordingly. 

[signature page follows] 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the latest date written
below. 
  

			
	GreenLight Biosciences Inc.
		
	By:	 	 

			
	Print Name:  [***]
	Title:  Chief Executive Officer
	
	Bayer CropScience

			
		
	By:	 	 

			
	Print Name:  [***]
	Title:  Business Development & Licensing

			
		
	By:	 	 

			
	Print Name:  [***]
	Title:  Multinational Accounts & Trait Licensing Manager

 Appendix A 

(Bee Health Know-how documents in secure electronic data room) 

[***]. 

 Appendix B 

(Bee Health Patents) 
  

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

					
	58862 AU 0000	  	2008325989	  	2008325989	  	Australia	  	Beeologics Inc.
					
	58862 AU 0001	  	2015200750	  	2015200750	  	Australia	  	Beeologics, Inc.
					
	58862 AU 0002	  		  	2017204098	  	Australia	  	Beeologics, Inc.
					
	58862 BR 0000	  		  	PI08173672	  	Brazil	  	Beeologics Inc.
					
	58862 CA 0000	  		  	2704858	  	Canada	  	Beeologics Inc.
					
	58862 DE 0000	  	2222852	  	088479712	  	Germany	  	Beeologics Inc.
					
	58862 DE 0001	  	2706114	  	131561839	  	Germany	  	Beeologics Inc.
					
	58862 DE 0002	  	6020080547329	  	131561854	  	Germany	  	Beeologics Inc.
					
	58862 DE 0003	  	6020080587363	  	131561805	  	Germany	  	Beeologics Inc.
					
	58862 EP 0002	  	2703489	  	131561805	  	Europe	  	Beeologics Inc.
					
	58862 EP 0003	  	2703490	  	131561854	  	Europe	  	Beeologics Inc.
					
	58862 EP 0006	  		  	182070177	  	Europe	  	Beeologics Inc.
					
	58862 FR 0000	  	2222852	  	088479712	  	France	  	Beeologics Inc.
					
	58862 FR 0001	  	2706114	  	131561839	  	France	  	Beeologics Inc.

									
					
	58862 FR 0002	  	2703490	  	131561854	  	France	  	Beeologics Inc.
					
	58862 FR 0003	  	2703489	  	131561805	  	France	  	Beeologics Inc.
					
	58862 GB 0000	  	2222852	  	088479712	  	United Kingdom	  	Beeologics Inc.
					
	58862 GB 0001	  	2706114	  	131561839	  	United Kingdom	  	Beeologics Inc.
					
	58862 GB 0002	  	2703490	  	131561854	  	United Kingdom	  	Beeologics Inc.
					
	58862 GB 0003	  	2703489	  	131561805	  	United Kingdom	  	Beeologics Inc.
					
	58862 HK 0000	  	1149047	  	11101987.0	  	Hong Kong	  	Beeologics Inc.
					
	58862 IL 0000	  	205594	  	205594	  	Israel	  	Beeologics, Inc.
					
	58862 IL 0001	  	240416	  	240416	  	Israel	  	Beeologics, Inc.
					
	58862 IL 0002	  		  	254692	  	Israel	  	Beeologics, Inc.
					
	58862 IN 0000	  	279131	  	1150MUMNP2010	  	India	  	Beeologics, Inc.

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

					
	58862 IT 0000	  	2222852	  	088479712	  	Italy	  	Beeologics Inc.
					
	58862 IT 0001	  	2706114	  	131561839	  	Italy	  	Beeologics Inc.
					
	58862 IT 0002	  	502018000024784	  	131561854	  	Italy	  	Beeologics Inc.
					
	58862 TR 0000	  	2222852	  	088479712	  	Turkey	  	Beeologics Inc.
					
	58862 TR 0001	  	2706114	  	131561839	  	Turkey	  	Beeologics Inc.
					
	58862 TR 0002	  	2703490	  	131561854	  	Turkey	  	Beeologics Inc.
					
	58862 US 0001	  	8097712	  	12222949	  	United States	  	Beeologics Inc.
					
	58862 US 0002	  	8507457	  	13332430	  	United States	  	Beeologics Inc.
					
	58862 US 0003	  		  	13932051	  	United States	  	Beeologics Inc.
					
	58862 ZA 0000	  	201003861	  	201003861	  	South Africa	  	Beeologics Inc.
					
	58864 AU 0000	  		  	2013248167	  	Australia	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 BR 0000	  		  	BR1120140255008	  	Brazil	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 CA 0000	  		  	2777448	  	Canada	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics, Inc.
					
	58864 CA 0001	  		  	2869831	  	Canada	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 CL 0000	  		  	201402751	  	Chile	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

					
	58864 CN 0000	  	ZL2010800565859	  	2010800565859	  	China	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 CN 0001	  		  	2013800311146	  	China	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 CN 0002	  		  	2015107517884	  	China	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 DE 0000	  	2488646	  	107798555	  	Germany	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 EP 0000	  	2488646	  	107798555	  	Europe	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 EP 0002	  		  	171883424	  	Europe	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 FR 0000	  	2488646	  	107798555	  	France	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 GB 0000	  	2488646	  	107798555	  	United Kingdom	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

					
	58864 IL 0000	  	219193	  	219193	  	Israel	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 IL 0001	  		  	235023	  	Israel	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 IN 0000	  		  	2141MUMNP2014	  	India	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 MX 0000	  	353880	  	MXA2012004378	  	Mexico	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 MX 0001	  		  	MXA2014000538	  	Mexico	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 MX 0002	  		  	MXA2014012364	  	Mexico	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 NZ 0000	  	700791	  	700791	  	New Zealand	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 RU 0000	  	2658771	  	2014144498	  	Russia	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

	58864 UA 0000	  	116206	  	a2014012247	  	Ukraine	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 US 0001	  	8962584	  	13446557	  	United States	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 US 0002	  	9662348	  	14606328	  	United States	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 US 0003	  		  	15498008	  	United States	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58864 ZA 0000	  	201407343	  	201407343	  	South Africa	  	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; and Beeologics Inc.
					
	58865 AU 0000	  	2010244122	  	2010244122	  	Australia	  	Beeologics Inc.
					
	58865 BR 0000	  		  	PI10077081	  	Brazil	  	Beeologics Inc.
					
	58865 CA 0000	  		  	2760883	  	Canada	  	Beeologics Inc.

									
	58865 DE 0000	  	6020100322262	  	107196206	  	Germany	  	Beeologics Inc.
					
	58865 FR 0000	  	2427180	  	107196206	  	France	  	Beeologics Inc.
					
	58865 GB 0000	  	2427180	  	107196206	  	United Kingdom	  	Beeologics Inc.
					
	58865 IL 0000	  	216154	  	216154	  	Israel	  	Beeologics Inc.
					
	58865 IN 0000	  	312922	  	9555DELNP2011	  	India	  	Beeologics Inc.
					
	58865 MX 0000	  	352992	  	MXA2011011839	  	Mexico	  	Beeologics Inc.
					
	58865 US 0001	  	8822426	  	13318636	  	United States	  	Beeologics Inc.

  

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

	58865 US 0002	  	9932579	  	14474205	  	United States	  	Beeologics Inc.
					
	60216 AR 0000	  		  	P140104134	  	Argentina	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As

Represented by the Secretary of
 Agriculture

							
	60216 AU 0000	  	2014341879	  	Australia	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of
 Agriculture

				
	60216 BR 0000	  	BR1120160099630	  	Brazil	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of
 Agriculture

				
	60216 CA 0000	  	2929533	  	Canada	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of
 Agriculture

				
	60216 CL 0000	  	10572016	  	Chile	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of
 Agriculture

							
	60216 CN 0000	  	2014800694294	  	China	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of Agriculture

				
	60216 EP 0000	  	148002140	  	Europe	  	Beeologics, Inc.

  

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

		  		  		  		  	 Monsanto Technology LLC
  

The United States of America, As Represented by the Secretary of Agriculture

					
	60216 IL 0000	  		  	245441	  	Israel	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of Agriculture

							
	60216 IN 0000	  	201617018026	  	India	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of Agriculture

				
	60216 MX 0000	  	MXA2016005778	  	Mexico	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of Agriculture

				
	60216 NZ 0000	  	719544	  	New Zealand	  	 Beeologics, Inc.
  

Monsanto Technology LLC The United States of America, As Represented by the Secretary of Agriculture

				
	60216 RU 0000	  	2016122053	  	Russia	  	 Beeologics, Inc.
  

Monsanto Technology LLC
 The United States of America, As
Represented by the Secretary of Agriculture

							
	60216 UA 0000	  	a201605962	  	Ukraine	  	 Beeologics, Inc.
 Monsanto Technology LLC

The United States of America, As

  

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

					
		  		  		  		  	Represented by the Secretary of Agriculture
					
	60216 US 0001	  	9540642	  	14532596	  	United States	  	 Beeologics, Inc.
 Monsanto Technology LLC

The United States of America, As
 Represented by the Secretary
of
 Agriculture

					
	60216 US 0002	  	10100306	  	15378513	  	United States	  	 Beeologics, Inc.
 Monsanto Technology LLC

The United States of America, As
 Represented by the Secretary
of
 Agriculture

									
					
	60216 US 0003	  		  	16125048	  	United States	  	 Beeologics, Inc.
 Monsanto Technology LLC

The United States of America, As
 Represented by the Secretary
of
 Agriculture

					
	60216 UY 0000	  		  	35817	  	Uruguay	  	 Beeologics, Inc.
 Monsanto Technology LLC

The United States of America, As
 Represented by the Secretary
of
 Agriculture

					
	60216 ZA 0000	  		  	201602878	  	South Africa	  	 Beeologics, Inc.
 Monsanto Technology LLC

The United States of America, As
 Represented by the Secretary
of
 Agriculture

					
	60220 AR 0000	  		  	P140104591	  	Argentina	  	Beeologics, Inc.
					
	60220 AU 0000	  	2014363992	  	2014363992	  	Australia	  	Beeologics, Inc.

							
				
	60220 BR 0000	  	BR1120160133870	  	Brazil	  	Beeologics, Inc.
				
	60220 CA 0000	  	2933527	  	Canada	  	Beeologics, Inc.

  

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

					
	60220 CL 0000	  		  	14402016	  	Chile	  	[***]
					
	60220 CN 0000	  		  	2014800748383	  	China	  	Beeologics, Inc.
					
	60220 DE 0000	  	3080147	  	148219769	  	Germany	  	Beeologics, Inc.
					
	60220 EP 0000	  	3080147	  	148219769	  	Europe	  	Beeologics, Inc.
					
	60220 FR 0000	  	3080147	  	148219769	  	France	  	Beeologics, Inc.
					
	60220 GB 0000	  	3080147	  	148219769	  	United Kingdom	  	Beeologics, Inc.
					
	60220 IL 0000	  		  	246136	  	Israel	  	Beeologics, Inc.
					
	60220 IT 0000	  	3080147	  	148219769	  	Italy	  	Beeologics, Inc.
					
	60220 MX 0000	  		  	MXA2016007676	  	Mexico	  	Beeologics, Inc.
					
	60220 NZ 0000	  		  	720971	  	New Zealand	  	Beeologics, Inc.
					
	60220 RU 0000	  		  	2016127297	  	Russia	  	Beeologics, Inc.
					
	60220 TR 0000	  	3080147	  	148219769	  	Turkey	  	Beeologics, Inc.
					
	60220 UA 0000	  	119253	  	a201607437	  	Ukraine	  	Beeologics, Inc.

							
				
	60220 US 0002	  	15103685	  	United States	  	Beeologics, Inc.
				
	60220 ZA 0000	  	201603924	  	South Africa	  	Beeologics, Inc.
				
	61478 AR 0000	  	P160101266	  	Argentina	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 AU 0000	  	2016257871	  	Australia	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 BR 0000	  	BR1120170237547	  	Brazil	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 CA 0000	  	2984907	  	Canada	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 CL 0000	  	27892017	  	Chile	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 CN 0000	  	2016800377700	  	China	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 EP 0000	  	167899400	  	Europe	  	Monsanto Technology LLC Beeologics, Inc.

  

									
	 Docket Number
	  	 Patent Number
	  	 Application Number
	  	 Country
	  	 Assignee

					
	61478 IL 0000	  		  	255401	  	Israel	  	Monsanto Technology LLC Beeologics, Inc.
					
	61478 IN 0000	  		  	201717043079	  	India	  	Monsanto Technology LLC Beeologics, Inc.

							
				
	61478 MX 0000	  	MXA2017014215	  	Mexico	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 NZ 0000	  	737164	  	New Zealand	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 RU 0000	  	2017141541	  	Russia	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 UA 0000	  	A201711656	  	Ukraine	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 US 0001	  	15571697	  	United States	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 UY 0000	  	36666	  	Uruguay	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 WO 0000	  	PCTUS2016030579	  	WIPO	  	Monsanto Technology LLC Beeologics, Inc.
				
	61478 ZA 0000	  	201707436	  	South Africa	  	Monsanto Technology LLC Beeologics, Inc.
				
	CSM62697 
US01	  	17013330	  	United States	  	Monsanto Technology LLC

 Appendix C 

(Delivery Patents) 
 [***]. 

 Appendix D 

(Insect Control Know-how) 

[***]. 

 Appendix E 

(Insect Control Patents) 
 [***] 

 Appendix F 

(Reasonable Access to Bayer employees) 
  

											
	 Name of Bayer employee
	  	 Primary Expertise
	  	Bayer to allow
access to 
employee
through 
(date)	 	  	Total
availability
(hours)	 
	 [***]
	  	Field Trial Design and Delivery + Relationship with beekeepers	  	 	12/30/2020	 	  	 	40	 
	 [***]
	  	Entomology/bee biology + Historical knowledge of Beeologics experience + Relationship with beekeepers	  	 	6/30/2021	 	  	 	40	 
	 [***]
	  	Regulatory Studies and Submission dossier	  	 	3/31/2021	 	  	 	15	 
	 [***]
	  	Regulatory Strategy	  	 	3/31/2021	 	  	 	15	 
	 [***]
	  	Biostatistics	  	 	3/31/2021	 	  	 	15	 
		  		  				  	  
	  
	 
	 Total
	  		  				  	 	125

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]